[STUDY_ID_REMOVED] 
CONFIDENTIAL 
The information contained in this document is regarded as confidential, and may not be  disclosed to another party unless such d isclosure is 
required to initiate the study, to conduct study-related activities, or  to comply with national, state, or local laws and regul ations.  Written 
authorization from the coordina ting site and sponsor is require d for disclosure otherwise. 
PT-PhI-II v05.22.12  
 
 
ELEVATE 
Evaluation of overcoming Limited migration and Enhancing 
Cytomegalovirus -specific dendritic cell Vaccines with 
Adjuvant TEtanus pre-conditioning in patients with newly-
diagnosed glioblastoma  
 
     
  Sponsor: PI – Duke Cancer Institute  
  Funding Source: NIH Grant  
  Protocol Source: PI - Duke Cancer Institute  
  Duke IRB#: Pro00054740  
  IND#: 
 [ZIP_CODE]  
 
Principal Investigator 
[INVESTIGATOR_664059], DO 
[EMAIL_566] 
  
Sub-Investigator(s) 
Annick Desjardins, M.D. 
[EMAIL_562] 
Henry Friedman, M.D.  
[EMAIL_563] 
Darell Bigner, M.D., Ph.D. [EMAIL_564] 
Katherine Peters, M.D. 
[EMAIL_560] Kristen Batich 
[EMAIL_12632] 
John Sampson, M.D., Ph.D. [EMAIL_565] 
Elizabeth Reap, Ph.D. 
[EMAIL_567]  
Statistician 
James E. Herndon II, Ph.D. 
[EMAIL_571] 
Lead Study Coordinator 
Jordan Parker, MS 
[EMAIL_12633] 
Regulatory Coordinator 
Rachel Hesler, Ph.D. 
[EMAIL_573] 
Therapeutic Material 
Manufacture Manager 
Gary Archer, Ph.D. 
[EMAIL_574] 
Data Manager 
Eric Lipp 
[EMAIL_575] 
 
 
Original version: 20140722  
Amended version 1: Date: 20140818 (CPC 
Mods)  
Amended version 2: Date: 20150109 (FDA 
Mods)  
Amended version 3: Date:20150506 (IRB Mods)  

ELEVATE 
Version: 20181120 
 
Amended version 4 
(AMD 001): Date: 20150518 (PI-
initiated) Randomization moved up; Blinding of pre-conditioning; tissue 
testing; updated information on where to send samples; 
Hepatitis C and autoimmune dis ease exclusion criteria added; 
and clarification on RT/TMZ therapy requirements for 
participation. 
Amended version 5 (AMD 005): Date: 20150702 (PI-
initiated) Added a 3
rd arm to provide basiliximab (Sections:  6, 7.2, 7.3, 8, 
9.1, 9.4, 10, 12.2, 12.6, 12.7, 13.1, 15, and 18.7) 
Added Curran Group Status to eligibility criteria (Section 11 
and 12.7.2 ) 
Updated language on source docs (Section 12.1) 
Updated withdrawal section to  match TMZ treatment plan 
(Section 12.6) 
Updated emergency unbli nding language (Section 13.3) 
Updated objectives with additional arm (Sections 8, 9, 12, and 
15) 
Made all subjects receive Td booster regardless of prior 
immunization history to mirror previous DC migration study 
(Section 9) 
Amended version 6 
(AMD 007) Date: 20150821 (PI-
initiated) To correct minor error on the cover page & update funding; to 
remove the company na me of Td (Sections 9 & 10); correct the 
name [CONTACT_664130] (Sections 4, 9 & 10); 
correct cell concentration error (Section 10); correct wording on 
randomization (Section 9); and clarified treatment summary 
table by [CONTACT_664090] (Section 12). 
Amended version 7 
(AMD 012) Date: 20151016 (PI-
initiated)  To include 1 red top tube prio r to each leukapheresis for 
immune monitoring (Section 12); to increase the enrollment and 
chemoradiation timeframe (Section 9, 12, & 18); corrected 
reference errors (Section 15). 
Amended version 8 
(AMD 014) Date: 20160210 (PI-
initiated) Clarified allowance of prevention of prior cancer treatment in 
exclusion criterion (Section 11); Use of antihistamines before, 
during and following vaccine administration recommendation 
(Section 12.7.3 ). 
Amended version 9 
(AMD 020) Date: 20160518 (PI-
initiated) Included blood to evaluate CCL3 levels prior to the Td booster 
given IM (Sections 12.2 & 12.7.5  ); allowed repeated 
leukapheresis if less than 3 vaccines generated from initial 
pheresis and again as needed for continued vaccinations, 
clarified that Tums is taken 3 times a day, and that a central line 
may be needed for the leukapheresis (Sections 9.1, 10.1 & 12.2 
), reduced the total number of va ccines from 20 to 10 (Sections 
6, 9.1, 12.2, and 12.3).  
Amended version 10 
(AMD 026) Date: 20160727 (PI-
initiated) Removed LSQ lab test  from study (Section 12.2) and included 
the already planned CMP with removal of LSQ (Section 
18.4.2 ); added IHC assays to tumor samples already being 
obtained (Section 12.1). 
Amended version 11 
(AMD 027) Date: 20160806 (PI-
initiated) To update the location of the cell processing suite with 
inclusion of associated abbreviations (Sections 4, 10.3, and 
10.4). 
Amended version 12 
(AMD 029) Date: 20160819 (PI-
initiated) To allow consenting and RT/TMZ  to occur within 6weeks of 
OR (Section 12.1). 
Amended version 13 
(AMD 32) Date: 20160915 (PI-
initiated) To remove reference to appe ndices with TMZ drug dosing 
information and removed sectio n in appendices.  Instead, 
referred the reader to the TMZ package insert uploaded in eIRB 
(Sections 9.1 and 18.4). 
Amended version 14 
(AMD 34) Date: 20161017 (PI-
initiated) To include tumor analysis up fro nt and at recurrence and add 
abbreviation for IDH (Sections 4 and 12). 
Amended version 16 
(AMD 45) Date:20170223 (PI- 
initiated) Changed the PI (title page, Sections 9.1.4 , 12.1, 13.2.1 , and 
13.3); changed the primary study coordinator and primary 
regulatory coordinator (title page); 
Amended version 15 
(AMD 49) Date: 20170324 (PI-
initiated) Randomization to Group III is closed due to results from a 
related study (Sections  9.1, 9.1.1, and 15); Due to the end to 
ELEVATE 
Version: 20181120 
 
enrollment in Group III, adjusted  the projected number of 
subjects in the study from 102 to 79.  Up to 100 people may 
sign the consent to reach this goal (Sections 9.1, 9.1.1 , and 15); 
Fixed inconsistencies in timing of Td Booster, which must 
occur before the DC vaccine #1 but can occur the same day as 
DC vaccine #1 (Sections 6, 9.1, and 12.7.5 ); Clarified the 
timing of blood draws for immune  monitoring and subclinical 
autoimmunity at DC Vaccine #1 (Sections 12.2 and 12.7.5 ); 
Removed the blood draws for CCL3 levels pre-/ post-Td 
Booster, CCL3 is still measured  from the IM blood taken at 
vaccine #[ADDRESS_896817]/CT imaging visits (Sections 12.2 
and 12.7.5 ); Clarified that after cycle 1, all remaining TMZ 
cycles will be 5 (±1) weeks (Section 9.1); Clarified the Follow-
up Period for subjects (Sections 12.4 and 12.5); Clarified the 
recording of AEs (Section 13.1); Clarified MMSE and immune 
monitoring in Table 4 (Section  12.2 ); For baseline MRI, 
changed “standard 5mm slices with 2.5mm spacing” to “per 
standard of care” (Sections 12.1 and 12.2); Clarified inclusion 
criteria regarding MRI at time of consent (Section 11 and 12.1 );   
Added “Patients should start RT within approximately 6 weeks 
of surgery” (Section 9.1) 
Amended version 16 
(AMD 58) Date: 20170523 (PI-
initiated) Made inclusion criteria for pregnancy more clear by [CONTACT_664091] [ADDRESS_896818] study-related procedure (Section 11);  Removed Curran 
as eligibility criteria but kept it as study assessment performed 
at time of consent (Sections 11 and 12.7.2 ); Clarified immune 
monitoring blood draws time points after completion of study 
vaccines (Sections 12, 12.4, and 12.7.5 ) 
Amended version 17 
(AMD 65) Date: 20170914 (PI-
initiated) Clarified language in inclusion cr iterion #1 regarding definitive 
resection (Section 11); Corrected error in Section 9.1.4  
regarding timing of recording AEs, which was missed in 
previous amendment (AMD 49); Clarified the information 
about subsequent therapi[INVESTIGATOR_664060]-up period (Section 12.4); Clarified length of radiation is 
approximately 6 weeks to make Section 9 and Section 12.6.1 
consistent; Updated descripti on of person delivering vaccine 
from MPACT to clinic and added that each vaccine will have a 
separate cooler (Section 10.4): Clarified dose adjustment of 
TMZ (Section 9.1.2 ) 
Amended version 18 
(AMD 73) Date: 20180406 (PI-
initiated) Study closed to enrollment (Section 9); Analysis plan updated 
(Section 15) 
Amended version 19 
(AMD 80) Date: 20181120 (PI-
initiated) Added that patient’s cells from the leukapheresis procedure can 
be transferred to the INTERCEPT trial (Pro00083828) if they 
become progressive and are eligible (Sections 9.1, 10.1, and 
12.3). 
 
ELEVATE 
Version: [ADDRESS_896819] OF ABBREVIATIONS ................................................................................................. 7  
5 PROTOCOL SYNOPSIS AND RESEARCH SUMMARY ................................................ 10  
6 STUDY SCHEMA................................................................................................................ 11  
7 BACKGROUND AND SI GNIFICANCE ............................................................................ 12  
7.1 Study Disease .................................................................................................................  12 
7.2 Study Agent ................................................................................................................... . 12 
7.2.1  Pre-Clinical Experience .......................................................................................... 18  
7.2.2  Clinical Experience ................................................................................................. 20  
7.3 Study Purpose/Rationale ................................................................................................ 24  
8 OBJECTIVES AND ENDPOINTS ...................................................................................... 26  
9 INVESTIGATIONAL PLAN ............................................................................................... 26  
9.1 Study Design ..................................................................................................................  26 
9.1.1  Randomization of Vaccine Site Pr e-Conditioning Strategies ................................. 29  
9.1.2  Definition of Unacceptable Toxicities .................................................................... 29  
9.1.3  Dose Modification .................................................................................................. 29  
9.1.4  Safety Considerations ............................................................................................. 29  
9.1.5  Missed Doses .......................................................................................................... 30  
9.1.6  Concomitant Medications ....................................................................................... 31  
9.1.7  Study Drug(s) Blinding ........................................................................................... 31  
9.2 Rationale for Selection of Dose, Regimen, and Treatment Duration ............................. 31  
9.3 Rationale for Correlative Studies ................................................................................... 31  
9.4 Definition of Evaluable Subjects,  On Study, and End of Study .................................... 32  
9.5 Early Study Termination ................................................................................................ 32  
10 STUDY DRUG .................................................................................................................... . 32 
10.1  Names, Classification, and Mechanism of Action ..................................................... 32  
10.2  Packaging and Labeling of Study Agents................................................................... 35  
10.3  Supply, Receipt, and Storage ...................................................................................... 35  
ELEVATE 
Version: [ADDRESS_896820](s) .................................................................................. 43  
12.6.1  Criteria for Early Withdrawal ................................................................................. 43  
12.6.2  Follow-up Requirements for Early Withdrawal ..................................................... 43  
12.6.3  Replacement of Early Withdrawal(s) ...................................................................... 44  
12.7  Study Assessments ..................................................................................................... 44  
12.7.1  Medical History ...................................................................................................... 44  
12.7.2  Physical Exam ......................................................................................................... 44  
12.7.3  Use of Antihistamines ............................................................................................. 44  
12.7.4  Radiologic Evaluations ........................................................................................... 44  
12.7.5  Immunologic Assessments...................................................................................... 45  
13 SAFETY MONITORING AND REPORTING .................................................................... 47  
13.1  Adverse Events ........................................................................................................... 47  
13.1.1  Reporting of AEs .................................................................................................... 47  
13.2  Serious Adverse Events .............................................................................................. 47  
13.2.1  Reporting of SAEs .................................................................................................. 48  
13.3  Emergency Unblinding of Investigational Treatment ................................................ 48  
13.4  Safety Oversight Committee (SOC) ........................................................................... [ADDRESS_896821] (DSMB) ............................................... 49  
14 QUALITY CONTROL AND QUALITY ASSURANCE .................................................... 49  
14.1  Monitoring .................................................................................................................. 4 9 
14.2  Audits......................................................................................................................... . 49 
14.3  Data Management and Processing .............................................................................. 50  
14.3.1  Study Documentation.............................................................................................. 50  
14.3.2  Data Management ................................................................................................... 50  
ELEVATE 
Version: 20181120 
 
4 
 14.3.3  Data Management Procedures  and Data Verification ............................................. 51  
14.3.4  Coding ..................................................................................................................... 51  
14.3.5  Study Closure .......................................................................................................... 51  
15 STATISTICAL METHODS AND DATA ANALYSIS ...................................................... 51  
15.1  Study Design Overview .............................................................................................. 52  
15.2  Analysis Sets .............................................................................................................. 52  
15.3  Patient Demographics and Othe r Baseline Characteristics ........................................ 53  
15.4  Treatments .................................................................................................................. 5 3 
15.5  Primary Objectives ..................................................................................................... 53  
15.5.1  Key Primary Objective:  Overall Survival .............................................................. 53  
15.5.2  Other Primary Objective:  Migration ...................................................................... 53  
15.5.3  Other Primary Objective:  Surviv al Among CMV Positive Patients ...................... 53  
15.5.4  Other Primary Objective:  Surviv al Among CMV Negative Patients .................... 54  
15.6  Secondary Objectives ................................................................................................. 54  
15.6.1  Key Secondary Objective:  PFS .............................................................................. 54  
15.6.2  Other Secondary Objective:  PFS Among CMV Positive Patients ......................... 54  
15.6.3  Other Secondary Objective:  PFS Among CMV Negative Patients ....................... 54  
15.7  Exploratory Objectives ............................................................................................... 54  
15.8  Interim Analysis ......................................................................................................... 55  
15.9  Sample Size Calculation ............................................................................................. 55  
15.9.1  Overview of Sample Size Requirements ................................................................ 56  
15.9.2  Key Primary Objective:  Survival ........................................................................... 56  
15.9.3  Other Primary Objective:  Migration ...................................................................... 57  
15.9.4  Other Primary Objective:  Surviv al Among CMV Positive Patients ...................... 58  
15.9.5  Other Primary Objective:  Surviv al Among CMV Negative Patients .................... [ADDRESS_896822] ...................................................................................................... 61  
ELEVATE 
Version: [ADDRESS_896823] Temozolomide Therapy .............................................................................. 72  
18.5  DCI Data and Safety Monitoring Plan ....................................................................... 73  
18.6  Duke PRTBTC DSMBplus Charter ........................................................................... 74  
18.7  Basiliximab Package Insert ........................................................................................ 75  
 
  
ELEVATE 
Version: [ADDRESS_896824] udy with a nearly complete response. ........................ 22  
Figure 5. TTP comparison between VICTORI Trial, AC TIVATE Trial, and a historical control.
............................................................................................................................... ........................ 22  
Figure 6. Basiliximab reduces TRegs in patien ts with GBM receiving DC vaccination. ............ 23  
Figure 7. Survival comparison of patients with GB M treated with PEPvIII-KLH loaded DCs 
(VICTORI Trial) with patients treated at Duke University with 81C6 anti-tenascin 131I labeled 
MAb. .......................................................................................................................... ................... [ADDRESS_896825] OF TABLES 
Table 1. Objectives and Endpoints ............................................................................................. .. 26  
Table 2. Storage of Study Agents .............................................................................................. ... 36  
Table 3. Dispensing of Study Agents ...........................................................................................  37 
Table 4. Schedule of Events ................................................................................................... ....... 41  
Table 5. Anticipated Accrual and Randomization Rates .............................................................. 57  
Table 6. Anticipated Accrual and Randomi zation Rate for CMV Positive Patients .................... 58  
  
ELEVATE 
Version: [ADDRESS_896826] Aspartate Aminotransferase 
AT Ambient Temperature 
AUC Area Under the Curve 
β-HCG Beta-Human Chorionic Gonadotropin 
BMT Bone Marrow Transplant 
BTSC Brain Tumor Stem Cells 
Ca++ Calcium 
CCL3 Chemokine (C-C motif) ligand 3 
cDNA Complimentary Deoxyribonucleic Acid 
CFA Complete Freund’s Adjuvant 
CFC Cytokine Flow Cytometry 
cGMP Current Good Manufacturing Practice 
CLIA Clinical Laboratory Improvement Act 
CLN Cervical lymph Nodes 
Cmax Maximum Concentration of Drug in Plasma or Serum 
CMP Comprehensive Metabolic Panel 
CMV Cytomegalovirus 
CNC Clinical Neurologic Change 
CNS Central Nervous System 
Con-A Concanavalin A 
CPC Cancer Protocol Committee 
CT Computed Tomography 
CTL Cytotoxic T-Lymphocyte 
CTQA Clinical Trials Quality Assurance 
DAR Drug Accountability Record 
DC Dendritic Cell 
DCI Duke Cancer Institute 
DLT Dose Limiting Toxicity 
DNA Deoxyribonucleic Acid 
DSMP Data Safety and Monitoring Plan 
DTH Delayed-type Hypersensitivity 
DUMC Duke University Medical Center 
EAE Experimental Autoimmune Encephalomyelitis 
EBRT External Beam Radiation Therapy 
ELISA Enzyme-Linked ImmunoSorbent Assay 
ELISPOT Enzyme-linked Immunospot 
EGFR Epi[INVESTIGATOR_664061]-KLH EGFRvIII conjugated to Keyhole Limpet Hemocyanin 
FACS Fluorescence Activated Cell Sorting 
FDA Federal Drug Administration 
ELEVATE 
Version: 20181120 
 
8 
 FEV Forced Expi[INVESTIGATOR_664062]-CSF Granulocyte Macrophage Colony Stimulating Factor 
HAMA Human Anti-Murine Antibody  
H&E Hematoxylin and Eosin  
HIV Human Immunodeficiency Virus 
HLA Human Leukocyte Antigen 
HMO Health Maintenance Organization 
I.C. Intracerebral 
ICS Investigational Chemotherapy Services 
I.D. Intradermal 
IDH Isocitrate Dehydrogenase 
IFN- Interferon-gamma 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IHC Immunohistochemistry 
IL-[ADDRESS_896827] Molecular Products and Cellular Therapi[INVESTIGATOR_664063]-adherent 
NCI CTC National Cancer Institute Common Toxicity Criteria 
ng NanoGram 
NIH National Institutes of Health 
NK Natural Killer 
OS Overall Survival 
OVA Ovalbumin 
PBLs Peripheral Blood Lymphocytes 
PBMC Peripheral Blood Mononuclear Cells 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reactions 
PD Progressive Disease 
PHA Phytohemagglutinin 
PFS Progression Free Survival 
PI [INVESTIGATOR_664064]: [ADDRESS_896828] of Care; Safety Oversight Committee 
TCR T cell Receptor 
TD Tetanus-Diphtheria  
TGF-β Transforming Growth Factor- β 
TH2 T helper type 2 
TMZ Temozolomide 
TNF-α Tumor Necrosis Factor- α 
TRegs Regulatory T cells 
TTP Time to Progression 
TTRNA Total Tumor mRNA 
VDLNs Vaccine-site Draining Lymph Nodes 
WBI Whole Body Irradiation 
  
ELEVATE 
Version: 20181120 
 
10 
 5 PROTOCOL SYNOPSIS AND RESEARCH SUMMARY 
Please see Research Summary section in eIRB. 
  
ELEVATE 
Version: 20181120 
 
11 
 6 STUDY SCHEMA 
 
Figure 1. Study Schema  
 
 
 
  

ELEVATE 
Version: 20181120 
 
12 
 7 BACKGROUND AND SIGNIFICANCE 
7.1 Study Disease 
 
Malignant primary brain tumors are more common than Hodgkin’s disease and account for more 
human deaths than melanoma or than cancer of the bladder or kidne y. Despi[INVESTIGATOR_179445], 
computer-guided tumor resection [ 3], high-dose external beam RT or brachytherapy, and multi-
mechanistic chemotherapy delivered at toxic doses , most patients with malignant primary brain 
tumors live <15 months from the time of diagnos is, and patients with recurrent tumors usually 
survive <12 weeks [ 4-9]. The estimated cost of treatment fo r each patient with a malignant brain 
tumor is between $30,[ADDRESS_896829] expensive medical therapy per quality-adjusted life-year sa ved currently provided in the 
[LOCATION_002] [ 10, 11 ]. Moreover, the non-specific nature  of conventional therapy for brain 
tumors often results in incapacitating damage to surrounding normal brain and systemic tissues 
[12, 13 ]. Thus, in order to be more effective, therap eutic strategies will have to precisely target 
tumor cells while minimizing collateral damage to neighboring eloquent cerebral cortex. The 
rationale for employing the immune system to targ et brain tumors is based on the premise that 
the inherent biologic specificit y of immunologic reactivity could meet the clear need for more 
specific and precise therapy . 
7.2 Study Agent 
 
Human Cytomegalovirus  pp65-lysosomal-associated me mbrane protein (pp65-LAMP) 
mRNA-pulsed autologous  dendritic cells  
 
DCs are potent immunostimulatory cells that con tinuously sample the antigenic environment of 
the host and specifically activate CD4+  and CD8+ T cells and B-cells [ 14, 15 ]. They are at the 
crossroads of many of the elegan t networks of the immune system, and DCs represent the most 
promising contemporary biologic entity for re alizing the promise of immunotherapy. Potent 
immune responses and encouragi ng clinical results have been seen in Phase I and II human 
clinical trials in systemic cancers[ 16-32 ]. 
 
Human CMV  is an endemic -Herpesvirus that does not usua lly cause significant clinical 
disease[ 33]. During primary maternal infection, however, human CMV  can cause severe 
encephalitis in fetuses and lead to  congenital brain defects. Human CMV  disease is also a 
significant problem in immunocompromised adults su ch as organ transplant recipi[INVESTIGATOR_664065][ 33]. Herpesviruses have also been impli cated in a number of human malignancies 
including lymphoma, nasopharyngeal cancer,  cervical cancer, and Kaposi’s sarcoma[ 34, 35 ]. 
Recently, expression of proteins unique to human CMV  has been reported within a large 
proportion of malignant tumors in cluding colorectal carcinoma, prostate cancer, and malignant 
astrocytomas[ 36-38 ]. Universal detection of the human CMV  immunodominant protein pp65, 
immediate early gene 1 protein (IE1), and severa l other early antigens wa s demonstrated using 
IHC in Grade II-IV astrocytomas[ 38]. Presence of the virus in these samples was confirmed with 
ISH, PCR for human CMV -specific glycoprotein B (UL55), el ectron microscopic detection of 
ELEVATE 
Version: [ADDRESS_896830] virions[ 38], and direct detection of the virus from fresh operative samples in the shell vial 
assay  (unpublished data). Human CMV  antigens were not detected  in surrounding normal brain 
samples, meningiomas, or brains affected by [CONTACT_664092], Alzheimer’s disease, paraneoplastic 
encephalitis, or Cryptococcal  cerebritis. 
 The presence of highly-immunogenic human CMV  antigens within MGs affords a unique 
opportunity to target these tumors immunologicall y. There is a vast amount of experience with 
both the safety and efficacy of  immunotherapy targeting human CMV [33], and the presence of 
this virus within brain tumors may allow this experience to be leveraged toward the effective eradication of MG expressing human CMV  antigens. Adoptive T cell th erapy has been used to 
safely and successfully protect against CMV  reactivation in myelodepleted BMT patients [ 39-
42]. In addition, T cell mediated immunotherapy ha s proven highly effective in the treatment of 
CMV -associated disease within the CNS[ 43] and in the treatment of acute CMV  infections[ 40, 
44]. Tumors associated with other human Herpesviruses , such as Epstein-Barr virus-associated 
lymphoma, including tumors within the CNS, have also been effectively treated and even large 
tumors have been cured by [CONTACT_179475][ 45-50 ]. More recently, a vaccine directed against the 
potent viral antigens of human papi[INVESTIGATOR_664066] s also been shown to reduce the incidence of 
human papi[INVESTIGATOR_27509]-related cer vical intraepi[INVESTIGATOR_179448] a prospective, randomized, 
double-blind trial[ 51]. 
 The potential for non-specific targeting of normal tissues is thought to be minimal in seropositive 
patients. After initial infection, CMV  establishes lifelong latency in the infected individual, with 
cells of the myeloid lineage cons tituting a major reservoir for pers istence of the virus. Virus can 
be detected within myeloid progenitors in the bone marrow, with a sma ll portion of these cells 
demonstrating viral DNA replication wit hout any detectable gene expression[ 52, 53]. Also a 
small proportion  (typi[INVESTIGATOR_897] 1 in 1,000 to 1 in 10,000) of peripheral blood monocytes can be 
found to contain CMV DNA, while detection of viral RNA  (gene expression) is not detected[ 54-
56]   
 Vaccination specifically against CMV [57-61 ] has effectively reduced th e risk of viral infection 
and transmission to fetuses in animal models [ 62-64 ] and in clinical trials[ 57, 61, 65-68 ]. Human 
clinical trials have also demons trated some benefit of administer ing neutralizing antibodies in the 
treatment of human CMV  infection[ 69-72 ], highlighting the importan ce of the development of 
vaccination strategies that el icit both cellular and humoral immune responses. DCs strongly 
activate both T cell and B-cell responses in vivo [15], and DCs pulsed in vitro  with CMV  antigens 
have been shown to be potent inducers of CMV -specific CTL responses in several studies[ 73-
77], in addition to our own work which is outlined below. 
 The use of RNA to encode tumor antigens for DCs was pi[INVESTIGATOR_179449]. Gilboa’s laboratory, but the abil ity of RNA-loaded DCs to stimulate potent antitumor immunity 
has been independently confirmed in murine and human systems [ 78-83 ]. In fact, there is 
accumulating evidence that RNA transfection repres ents a superior method for loading antigens 
onto DCs [ 80, 84]. This novel and innovative approach to DC antigen loading has multiple 
conceptual advantages over other forms of antig en delivery as well. RNA-based antigen loading 
does not require knowledge of majo r MHC restriction, and responses are not restricted to single 
MHC haplotypes or to a narrow B or T cell repertoire. This dive rsity increases the likelihood of 
ELEVATE 
Version: 20181120 
 
14 
 inducing effective and sustained antitumor immu ne responses by [CONTACT_664093] T cells [ 85-87 ]. Furthermore, in direct comparisons, RNA-loaded DCs have 
been found to be better stimulators of antig en-specific T cells than other approaches [ 84]. 
Finally, RNA also carries a significant safety ad vantage, not possessed by [CONTACT_664094], in that it cannot be  integrated permanently into th e host genome. In addition to the 
preliminary data we present below, Kobayashi et al. [88] have demonstrated that tumor mRNA-
loaded DCs can elicit a specific CD8+ CTL res ponse against autologous tumor cells in patients 
with MG.  
Temozolomide 
 
TMZ, a methylating agent with good blood-brain ba rrier penetration, has recently been shown to 
increase survival by a small, but statistically significant, 2.5 months  in a subset of patients with 
newly-diagnosed GBM if given in conjunction with RT following initial resection of the 
tumor[ 2, 89, 90]. Leukopenia is essentially the only  known human toxicity of TMZ. Although 
initially counter-intuitive, th is TMZ-induced leukopenia may actually be advantageous in 
treating patients with i mmunotherapy due to the subsequent homeostatic proliferation it induces. 
In this protocol patients will receive standa rd of care doses of TMZ concurrent with RT 
following initial resection of the tumor. We believe that the myelosuppression induced by 
[CONTACT_664095], if carefully time d before vaccination will actually enhance the 
proliferation and maintenance of these tumor-sp ecific T cells through the natural forces that 
drive T cell homeostatic prolif erative recovery. In addition, TMZ has also been shown to 
preferentially deplete T Regs[91]. Thus, this combination strategy will uniquely exploit the toxicity 
of one effective therapy for GBMs, TMZ, to  enhance another already promising therapy, 
immunotherapy. In preparation for this protocol, we have evalua ted, in animal models, TMZ and 
sublethal WBI, as a positive control, as met hods for induction of treat ment-induced lymphopenia 
in order to determine the ability of TMZ- induced lymphodepletion to enhance active and 
adoptive immunotherapy. These studies were ini tially performed in a murine T cell receptor 
transgenic model in which the antig en-specific T cells can be followed in vivo  in mice receiving 
adoptive transfer of lymphocyt es. In this model system, we  found that adoptive lymphocyte 
transfer coupled with DC vaccination (DC + ALT) is a potent mechanism for inducing antigen-specific T cell expansion after TMZ treatment. TM Z was found to be an effective agent for 
inducing homeostatic proliferati on of transferred CD4+ and CD8+ T cells and for enhancing DC 
or peptide vaccinations with or without ALT ( Figure 2 ). 
  Markedly elevated levels of antigen-specific T cells could be achieved and maintained in mice 
receiving ALT after therapeu tic TMZ-induced lymphodepleti on compared to normal hosts 
receiving ALT. The precursor frequency of OVA- specific CD8+ T cells in the peripheral blood 
of untreated mice receiving OVA pep tide vaccine after transfer of  OT-I transgenic T cells was 
1.5%. Mice pretreated with TMZ and given OVA pe ptide vaccine had achieved a mean precursor 
ELEVATE 
Version: 20181120 
 
15 
  
Figure 2. Homeostatic lymphodepletion induced by [CONTACT_570046]-specific immune 
responses.  Untreated mice or mice receiving n on-myeloablative high-dose temozolo mide treatment (5 days x 60 
mg/kg) were administered a mixture of  OVA-specific and normal lymphocytes intravenously and received either no 
vaccine, vaccination with DCs transfect ed with OVA RNA, or OVA peptide vaccination in complete Freund’s 
adjuvant.  The peripheral blood of treated animals was collected and analyzed 6 da ys after vaccination for the 
expansion of OVA-specific T cells in the circulation using αCD8 monoclonal antibodies and a specific tetramer.  As 
shown above, mice treated with  temozolomide prior to ALT demonstrated markedly increased T cell expansion after 
vaccination compared to untr eated hosts receiving ALT. 
 
 frequency of 54%, exhibiting markedly increas ed levels of OVA-specific T cells in the blood 
(P<0.0001). Similar results were found in mice recei ving DC vaccination, with untreated animals 
having an average precursor frequency of 3.6%  and TMZ pretreated animals achieving an 
average of 11.9% OVA-specific CD8+ T cells  after a single vacci nation. These results 
demonstrate that active and adoptive imm unotherapy administered during hematopoeitic 
recovery from TMZ treatment may be a very  effective way to enhance the efficacy of 
immunotherapy. 
 
Basiliximab (Simulect®) 
 
Basiliximab (Simulect®) is a chimeric (murine/human) monoclonal antibody (IgG1K), produced 
by [CONTACT_12060], that functions as an immunosuppressive agent, specifically 
binding to and blocking th e interleukin-2 receptor α-chain (IL-2R α, also known as CD25 
antigen) on the surface of activated T-lymphocytes.  Basiliximab has been most frequently used as  an immunosuppressant in combination with other 
broadly active immunosuppressants, such as cyclos porine and corticosteroids that may target the 
redundancy pathways for effector T cell development[ 92]. As an immunosuppressant, it is 
administered within 2 hours pr ior to transpla ntation surgery (Day 0) and the second dose 
administered on Day [ADDRESS_896831]-transplantation. The re gimen of basiliximab wa s chosen to provide No Vaccine
100101102103104
CD4 APC
R40.74%
CD8 APC100101102103104
CD4 APC
R42.11%DC OVA RNA
100101102103104
CD8 APC
R413.92%OVA peptide/CFA
100101102103104
CD8 APC
R479.86%OVA peptide/CFA
100101102103104
CD8 APC
R40.79%No Vaccine
100101102103104
CD8 APC
R429.80%DC OVA RNACD8 APCUntreated Temozolomide
ELEVATE 
Version: [ADDRESS_896832] or T cells may be expected to up-
regulate IL-2R α expression and be inhibited. Thus, we be lieve, and our preclinical animal studies 
support, that the activity of IL-2R α blockade is entirely dependen t on the context in which it’s 
given. We believe that blocking IL-2R α signaling during recovery from TMZ-induced 
lymphopenia will predominantly impact the recovery, function, and survival of T Regs without 
having negative effects on the recovery, function a nd survival of tumor-specific T cells activated 
through vaccination or through cross- priming at the tumor site wher e the role of other cytokines 
will predominate.  Please see package insert in the appendices (see Section 18.7). 
 
111Indium-labeling of Cells for in vivo Traffi cking Studies 
 
The in vivo  distribution of DCs will be evaluated using 111Indium (111In)-labeled pp65-LAMP 
mRNA loaded mature DCs. 111In-labeled DCs have been used  extensively for evaluation of 
adoptively transferred tumor infiltr ating lymphocytes, natural killer  cells, granulocytes, dendritic 
cells, and whole blood leukocytes, for in vivo  localization studies in humans[ 93-95 ].  DCs will be 
labeled at the Duke Radiopharmacy Lab according to standardized protocols. Briefly, 2 x 107 
pp65-LAMP mRNA loaded mature  DCs will be labeled with 111In (50 μCi / 5 x 107 DCs) 
(Nycomed-Amersham, Chicago, IL) prior to injec tion. Intradermal DC inj ections sites will be 
carefully marked at 10 cm from the groin crease.   Gamma camera (dual-headed) images will then 
be taken immediately after injections, and at [ADDRESS_896833] ions to compare DC 
migration from the inguinal intradermal inj ection sites to the i nguinal lymph nodes (SOP-
DBTIP-078 “Administration of 111In-labeled Dendritic Cells for Trafficking”).  Regions of 
interest will be analyzed using decay corrected counts.  These co rrelative studies are designed to 
determine the effects of skin site preparation have on DC migration. 
 
Tetanus-diphtheria toxoid (Td) 
 The current use of Td toxoid is for active immuni zation in children and a dults against infection 
with the bacteria Clostridium tetani  and Corynebacterium diphtheria . Tetanus infection is 
manifested primarily by [CONTACT_664096] a potent exotoxin released by C. 
tetani . Diphtheria is an acute toxin-mediated infe ctious disease caused by [CONTACT_34525] C. 
diphtheriae . Protection against disease is  due to the development of neutralizing antibodies to the 
diphtheria toxin. Td toxoids adso rbed are readily available as several approved administrations 
[i.e. Daptacel (DTaP), Infanrix (DTap), Tenivac (Td adult), Boostrix (Tdap)] [ 96, 97]. Protection 
against disease is due to the de velopment of neutralizing antibodies  to the tetanus toxin. A serum 
tetanus antitoxin level of at le ast 0.01 IU/mL, measured by [CONTACT_664097], is considered 
the minimum protective level. A level ≥0.1 IU/mL by [CONTACT_34527] 
[98]. A serum diphtheria antitoxin level of 0.01 IU/m L, measured by [CONTACT_34526], is the 
lowest level giving some degree of protection; a level of 0.1 IU/mL by [CONTACT_664098]. Diphtheria antitoxin levels ≥1.0 IU/mL by [CONTACT_34529]-
term protection [ 99]. 
 Following deep s.c./i.m. administration of the te tanus toxoid vaccine, toxoid molecules are taken 
up at the vaccination site by [CONTACT_34530], which are professional an tigen-presenting cells. 
Within these cells, they are processed th rough the endosomal pa thway (involving the 
phagolysosome) where they are bound to MHC type II molecules on the surface of DCs. The 
ELEVATE 
Version: 20181120 
 
17 
 MHC II:toxoid complex then migrates to the cell surface. While this process is happening within 
the cell, the now activated mature  DC at the vaccine site migrat es along lymph channels to the 
draining lymph node where they encounter naive T H2 cells, each with their own unique TCR. 
Identifying and then binding of th e MHC II:toxoid to the specific T H2 receptor then activates the 
naive T cell, causing it to proliferate. Simulta neously, toxoid molecules not taken up by [CONTACT_664099] 
B cells, each with their own unique B-cell re ceptor (BCR). Binding to the B cell through the 
specific immunoglobulin receptor that recognizes teta nus toxoid results in the internalization of 
toxoid, processing through the endosomal pathwa y and presentation on the cell surface as an 
MHC II:toxoid complex, similarly to DCs undergoing the same process [ 100].  
 These two processes occur in the sa me part of the lymph node with  the result that the B cell with 
the MHC II:toxoid complex on its surface now co mes into contact [CONTACT_179481] T
H2 whose 
receptors are specific for this complex. The proc ess, termed linked reco gnition, results in the T H2 
activating the B cell to b ecome a plasma cell with the producti on initially of IgM, with a later 
switch to IgG antibodies produced. Additionally, a s ubset of these B cells becomes memory cells 
[100]. 
 The novelty of using Td toxoid va ccination lies in the ability of  this potent recall antigen to 
enhance antitumor responses as part of a can cer vaccination protocol. Td toxoid induces an 
inflammatory milieu within the intradermal vacci ne site, thereby [CONTACT_664100]-specific DCs. Additionally, in the context of vaccinating the host with tumor-
derived peptides, conditioning th e vaccine site with Td toxoid has demonstrated enhanced 
immunogenicity with these peptides.   Our data from the ATTAC clinical trial (D uke IRB Protocol # Pro00003877) demonstrating the 
capacity to enhance DC migration to VDLNs via Td pre-conditioning of the vaccine site offer 
potential therapeutic interventions whereby [CONTACT_664101]. In a 
completed randomized clinical trial, we found that migration of in jected DCs to VDLNs 
following vaccine site pre-conditioning with Td t oxoid was significantly increased compared to 
controls and that the efficiency of DC migrati on was strongly associated with clinical outcomes 
of patients with newly-diagnosed GBM, the most  fatal type of malignant brain tumors. To 
address this observation, we took our Td pre-co nditioning platform back into the preclinical 
setting using transgenic mouse models and were  able to corroborate the effects of Td pre-
conditioning on increasing the lymph node hom ing of intradermally administered DCs. 
Moreover, Td administration at a single vaccine site increases the migration of a bilateral DC 
vaccine to both inguinal lymph nodes. Regardless of  the side of the Td intradermal skin prep, DC 
migration to bilateral inguinal VDLNs was equa lly increased, supporting a systemic response to 
recruit peripherally administered DCs.  
 
Our Td pre-conditioning platform in the contex t of DC vaccination also  elicited superior anti-
tumor responses compared to controls receivi ng DC vaccines without Td pre-conditioning. In 
our clinical trial, patients with newly-diagnosed  GBM who were administered the Td skin prep 
before DC vaccination revealed significantly longer progression- free and overall survival rates 
compared to the control cohort. In evaluating th e relationship between DC migration and clinical 
ELEVATE 
Version: [ADDRESS_896834] positive corre lation between levels of DC migration and 
survival. In our preclinical model, Td pre-cond itioning prior to vaccination with tumor antigen-
specific DCs dramatically suppressed the growth  of established and highly aggressive B16-
F10/OVA tumors. The use of Td with a DC vaccine  increased antitumor re sponses in an antigen-
specific manner, as non-specific DC vaccines were  not potentiated with Td pre-conditioning. 
Furthermore, in a challenge setting, where mice ar e administered the treatment platform prior to 
challenge with tumor inoculation, Td pre-conditio ning at the vaccine site induced a significant 
survival benefit compared to controls. 
     
7.2.[ADDRESS_896835] emic immunization using DCs co-cultured with 
uncharacterized tumor homogenate[ 101], whole tumor RNA[ 102], unidentified peptides eluted 
from tumor cells by [CONTACT_179484][ 103], or a distinct peptide encompassing the tumor-
specific EGFRvIII mutation[ 104] have been shown to induce humoral and cell mediated 
systemic immune responses and to prolong th e survival of rodents with brain tumors. 
 In our laboratory[ 101], inbred VM/Dk mice received thr ee or four weekly intraperitoneal 
injections of autologous bone marrow-derive d DCs transiently co-cultured with tumor 
homogenate. The homogenate was derived from  a syngeneic murine astrocytoma cell line 
derived from a spontaneously occurring astr ocytoma in the inbred VM/Dk mouse strain. 
Splenocytes from mice immunized in this way were  able, in vitro, to lyse the astrocytoma cell 
line that was used to generate the tumor hom ogenate. They were also able to lyse other 
astrocytoma cell lines derived from the same inbr ed mouse strain, but they had no effect against 
syngeneic fibroblasts. Similarly, these immuni zed mice also demonstrated a significantly 
increased antibody titer against th e astrocytoma cell line used to  generate the homogenate. In 
addition, mice immunized with DCs transiently co -cultured with tumor homogenate that were 
subsequently challenged with a lethal dose of this astrocytoma cell line intracerebrally were 
found to have a median survival >160% longer th an those immunized with DCs cultured without 
tumor homogenate ( P=0.016). In addition, 50% of the mice treated with the tumor homogenate-
supplemented DCs survived long-term without any evidence of tumor growth  and also survived 
a rechallenge of tumor cells i ndicating that a sustained antitu mor immune response had been 
established. These findings are especially significant  in light of the fact that the astrocytoma cell 
line used is known to secrete the immunosuppressive agent TGF-  which is secreted by [CONTACT_593135][ 105-109 ]. 
 In another report from our laboratory[ 102], C57BL/[ADDRESS_896836] in 
vitro cytotoxicity assays again revealed that splenocytes harvested from mice immunized with 
DCs transiently co-cultured with either tumo r-derived homogenate or whole tumor RNA were 
able to lyse B16F10 melanoma cells but not unrelated tumor cells from the same MHC) 
background. In this experiment, mice immunized with autologous bone-m arrow derived DCs co-
cultured with tumor homogenate or whole tu mor RNA increased median survival by >233% 
(P=0.0006) and 48% ( P=0.0001), respectively, relative to mi ce immunized with DCs co-cultured 
with tumor homogenate or whole tumor RNA deri ved from an unrelated tumor with the same 
MHC background. In addition, 8/13 (61.5%) in the specific homogenate group and 4/10 (40%) in 
ELEVATE 
Version: 20181120 
 
19 
 the specific RNA group survived  beyond the endpoint of the study without evidence of tumor. 
Immunization of mice with pre- existing tumors with specific tumor homogenate also 
demonstrated the potency of this immunizati on approach by [CONTACT_179486] 62.5% 
relative to controls. In these mi ce an inflammatory infiltrate co mposed of mononuclear cells and 
polymorphonuclear leukocytes was identified only  in mice treated with DCs co-cultured with 
tumor homogenate that matched the intracerebral tumor challenge. 
 In a recent report from another laboratory[ 103], the survival of tumor-bearing rats injected 
subcutaneously with autologous bone marrow-deri ved DCs co-cultured with peptides eluted 
from tumor cells with a gentle acid wash was significantly prolonged compared to tumor-bearing 
rats receiving equivalent number s of DCs co-cultured with peptides acid-eluted from normal 
astrocytes ( P< 0.05).  Median survivals in these groups  were 35 and 22 days respectively. In 
addition, three of the twelve ra ts (25%) treated with DCs co-c ultured with acid-eluted tumor 
peptides remained alive at the end of the expe riment. In addition, immu nohistochemical analysis 
of five animals from each group in this experiment documented an increased peritumoral and intratumoral infiltration of CD8+ T cells, and to a lesser extent CD4+ T cells and macrophages, in 
the group treated with DCs co-cultured with pe ptides acid-eluted from tumor cells when 
compared to controls.   
 
Inhibition of T Reg Function with Anti-CD25-spec ific Monoclonal Antibodies 
We have reported that our murine model of g lioma indeed recapi[INVESTIGATOR_664067]-induced changes to 
the human peripheral blood CD4 and T Reg compartments. Specifically, tumor-bearing mice 
exhibit CD4 lymphopenia, while CD4+CD25+Foxp3+GITR+ TRegs come to represent an increased 
fraction of the peripheral blood CD4+ T cells that remain, despi[INVESTIGATOR_664068]. Extending study to other sites, similar phenomena are observed in the spleens and CLN, 
while the reverse scenario emerges in bone marrow.  
 
We employed this model to investigate the in vivo effects of T Reg removal on anti-glioma 
immune responses. The current doctrine is that effective depletion of T Regs may be achieved 
simply by [CONTACT_664102]-CD25 mAb[ 110, 111]. Likewise, in peripheral, non-
CNS tumor models, the administration of anti- CD25 mAb has been employed in attempts to 
remove T Regs and has effectively elic ited prolonged survival to subcutaneous tumor 
challenge[ 112-114 ]. These studies, however, predated our ability to examine Foxp3 expression 
in T Regs with antibody staining.     
 
 Following in vivo administration of anti -CD25 mAb (PC61), we discovered that 
CD4+Foxp3+GITR+ cells failed to entirely disappear, desp ite the present thi nking. Instead, they 
persisted at significant levels in all sites tested. When isolated based on CD4 and GITR 
expression, however, these cells de monstrated none of the typi[INVESTIGATOR_664069]4+CD25+GITR+ TRegs in vitro. Accordingly, systemic anti-CD25 mAb proved capable of 
enhancing T cell proliferation, IFN- γ production and glioma-specific CTL responses in treated 
mice. These effects translate to spontaneous tumo r rejection in a murine  model of established 
intracranial glioma ( Figure 3 ). 
 
Furthermore, when combined with a DC-bas ed immunization strategy, anti-CD25 mAb elicited 
glioma rejection in 100% of challenged  mice without attend ant induction of EAE[ 115, 116]. 
Systemic anti-CD25 mAb administration therefore appears to counter the  suppressive effects of 
ELEVATE 
Version: 20181120 
 
20 
 TRegs without comprehensively elimin ating the cells in vivo. This activity proves permissive for 
potent antitumor immunity in a murine glioma model that aptly recapi[INVESTIGATOR_664070]-induced 
changes to the CD4 and T Reg compartments. 
 
 
Figure 3. PC61 in vivo extends surv ival and permits tumor rejection in  a murine model of intracranial 
glioma.  A. VM/Dk mice (n=10 per grou p) received i.p. PC61 or isotype control on Day -4. On Day 0, all mice were 
challenged intracranially with 10,0 00 syngeneic SMA-560 astrocytoma cells. Anti-CD25 produced 50% long-term 
survivors with no eviden ce of tumor. Differences in su rvival curves are significant (p =0.0002). B. Effects of PC61 
in a therapeutic model. Treated mice (n =7) received i.p. PC61 three days follo wing tumor implantation, when tumor 
was established. PC61 significantly extended median survival (p=0.0003) and produced nearly 15% long-term survivors with no evid ence of tumor. C. Combination of anti-C D25 and DC vaccine produce 100% survival 
following intracranial tumor challenge. VM/Dk mice (n=5 per group) were adminisitered 0.5 mg PC61 (anti-CD25) 
or isotype control antibody i.p. on Da y -10. On Day -7, mice were vaccinated with 2.5x105 DC electroporated with 
total tumor RNA from the SMA-[ADDRESS_896837] . Anti-CD25 (p=0.0198) and DC vacci ne (p=0.0153) alone each produced 
significant survival benefits, but the combination of the two elicited 100% long-term survival (p=0.0018). 
 
 
7.2.2 Clinical Experience 
Prior Experience in Patients with Intracerebral Tumors 
The occurrence of human DCs in the peripheral blood is low (0.15% of circulating mononuclear 
cells), and procedures to isolate circulating DCs are cumbersome, relying on negative selection 
techniques to deplete the mononuclear cell fraction of contaminating monocytes and 
lymphocytes. Furthermore, brain tumor patients  are characteristically immnosuppressed either 
from the use of steroids or due to the fact that malignant brain tumors secrete 
immunosuppressive agents like TGF- . We have been using a simple method described 0102030405060708090100
0 5 10 15 20 25 30 35 40 45 50
DaysNon-Depleted
        DepletedPercent SurvivingTreg-
0102030405060708090100
0 5 10 15 20 25 30 35 40 45 50
DaysNon-Depleted
        DepletedPercent Survivin gTreg -A
B0102030405060708090100
0 5 10 15 20 25 30 35 40 45 50
DaysNon-Depleted
        DepletedPercent SurvivingTreg-
0102030405060708090100
0 5 10 15 20 25 30 35 40 45 50
DaysNon-Depleted
        DepletedPercent Survivin gTreg -A
B
0102030405060708090100
0 5 10 15 20 25 30 35 40 45 50 55 60
DaysVaccine only
Vaccine + Anti-CD25
PBS
Anti-CD25 onlyPercent surviving
ELEVATE 
Version: 20181120 
 
21 
 previously[ 117], to generate human DCs by [CONTACT_664103]-
CSF and IL-4. We have compared the ability to generate DCs from patients with malignant brain 
tumors and patients undergoing craniotomy for n on-tumor related procedures. The phenotype of 
DCs from both tumor and normal populations were  identical and were ch aracterized as being 
highly positive for HLA-ABC and HLA-DR, the co-stimulatory molecules CD80 and CD86, and the DC/monocyte marker CD11c, but negative for the monocyte marker CD14. The cells were 
negative for the B and natural killer (NK) cell lineage mark ers, CD19 and CD56, respectively, 
which is consistent with published DC phenotypes. 
 
DC immunotherapy in patients with  MGs has been evaluated only a few studies. In the published 
study by [CONTACT_36868]. [118], patients received biweekly intrad ermal injections of peripheral blood 
derived DCs pulsed with uncharacterized peptides eluted from the surface of autologous glioma 
cells by [CONTACT_179488]. All patients were re quired to complete a course of RT and were off 
steroids at the time of immunization. Toxicity  was minimal and included only mild fever and 
lymphadenopathy. There was no clinical or radiographic evidence of autoimmune 
encephalomyelitis in any patient and no serious  adverse events occurred. The immunization 
resulted in enhanced CTL activity  in 4/[ADDRESS_896838] infiltrated the patient’s tumors  whom underwent reoperati on after immunization. 
Although this study was performed in a selected popul ation of patients, the median survival of 
455 days in the treated group compared very favo rably with an institutional control group where 
median survival was only 257 days. Similarly, when immunized patients were compared to 
expected outcome per Curran’s recursive parti tion analysis, which cont rols for known prognostic 
factors (Karnofsky Performance Status, histology, su rgery, mental status, etc), the results still 
appeared quite favorable. Unfortunately, no clin ical responses were seen and any antigen-
specific immune response could not be character ized because the immunizing antigens were not 
characterized. 
 
A study by [CONTACT_179489].  (2001) [ 119]used autologous DCs fused with  autologous tumor cells as 
an immunogen in an 8 patient trial. The immuniza tion schedule consisted of 3 to 7 vaccinations 3 
weeks apart given intradermally. All vaccinations were well tolerated.  
 
In another Phase I/II trial, tumor lysate pulse d DCs were given to ten patients who received 
immunizations every three weeks for a minimu m of one and a maximum of [ADDRESS_896839] tumor lysate-pulsed DCs were increased in 
two patients[ 120]. In a more recently published study, pati ents with GBM were treated with 1 x 
106 to 1 x 107 DCs pulsed with acid eluted  autologous tumor peptides[ 121]. There was no 
evidence of DLT or serious adverse events. On e patient had an objective clinical response 
documented by [CONTACT_9252], and si x patients developed measurable systemic 
antitumor CTL responses. 
 
In a more recent study, Kikuchi et al.[ 122] investigated the safety and clinical response to 
immunotherapy using fusions of DCs and glioma cells combined with recombinant human IL-12 
for the treatment of MG. Fifteen patients with MG  participated in this study. Cultured autologous 
glioma cells were established from surgical sp ecimens in each case. Fusion cells were prepared 
from DCs and glioma cells us ing polyethylene glycol. All patients received fusion cells 
intradermally on day 1. IL-12 was injected subcutan eously at the same site on days 3 and 7. No 
ELEVATE 
Version: 20181120 
 
22 
 serious adverse effects were observed. In four  patients, magnetic resonance imaging showed a 
greater than 50% reduction in tumor size. One patient had a mixed response. In our ongoing 
Phase I/II clinical trial  (BB IND 9944) patients  with newly-diagnosed MG s are vaccinated with 
mature DCs loaded with a peptide spanning the fusion junction of EGFRvIII conjugated to 
keyhole limpet hemocyanin (PEPvIII-KLH) (500 mcg/immunization), mixed with GM-CSF (approx. 150 mcg/immunization). EGFRvIII is a tumor specific antigen, which is expressed on 
approximately 47% of all MGs. The vaccination prot ocol consists of [ADDRESS_896840] been enrolled with 16 completing vacci nation with no adverse 
events. No patient showed a positive delayed- type hypersensitivity reaction to KLH or PEPvIII 
before vaccination and of the evaluable patients af ter vaccination, 14/15 ( 93.3%) patients reacted 
to KLH and 11/15 (73.3%) reacted to PEPvIII. In vitro  proliferation in response to PEPvIII was 
seen in 11/12 (92%) and to KLH in 9/12 (75% ) of patients tested. Two patients, one with 
anaplastic astrocytoma and one with GBM with re sidual radiographic diseas e after resection, and 
 
Figure 4. Patient from prior vaccination study with a nearly complete response .  Progressive MG after radiation 
and temozolomide (top) with nearly complete response, 3 months after PE PvIII-pulsed DC vaccine (bottom). 
 
[ADDRESS_896841] ORI Trial, ACTIVATE Trial, and a historical control.  TTP comparison in 
patients treated with PEPvIII-KLH loaded DCs (VICTO RI Trial), patients treated with PEPvIII-KLH alone 
(ACTIVATE Trial), and a historical control group that  had a 95% resection of an EGFRvIII-positive tumor.   There 

ELEVATE 
Version: 20181120 
 
23 
 was no significant difference in the TTP between the patie nts in the VICTORI and ACTIVATE trials, but both were 
significantly better than historical controls (P<0.001). 
radiation, have had a nearly complete respons e in our prior vaccina tion study which also 
included the use of chemotherapy agents such as TMZ  (Figure 4). These patients have remained 
stable for 174.9 and 217.3 weeks. Of the 14 patients  without radiographically evident disease, 
4/14  (28.6%) have not progressed at 102.7, 171.3, 180.7, 430.7 weeks with a median overall 
time to progression of 10.4 months comparing favor ably with a historical unvaccinated cohort  
(EGFRvIII positive and gross total resection) that had a median TTP of 7.1 months  (n=39).  
(Figure 5)  For patients with GBM, the medi an survival time was 20.0 months which compares 
favorably with recently published trials evalua ting newly-diagnosed pati ents with GBM treated 
with GLIADEL®(13.9 months)[ 1]; radiation and concurrent TMZ (14.6 months)[ 2]; or 
radiolabeled anti-tenascin monoclonal antibodi es performed at Duke University  (18.3 
months)[ 123] (Figure 7). This Phase I study has been completed. No toxicity has been seen 
(Figure 6).  PBMC were isolated and analyzed by [CONTACT_4133].  CD4+ is shown as percent of 
lymphocytes and T Regs are shown as percent of CD4.  T Regs defined as CD4+CD25+Foxp3+.  
Based on these results, the dose for this study will be 20 mg. 
 
 
Figure 6. Basiliximab reduces TRegs in pati ents with GBM receiving DC vaccination.  (B=Basiliximab, 
V=vaccine) 

ELEVATE 
Version: 20181120 
 
24 
 0 50 100 150 200 250 300 3500102030405060708090100
VICTORI DC TrialPercent Surviving
79 Weeks110.8 Weeks
81C6 MAb Trial
Weeks 
Figure 7.  Survival comparison of patients with GBM treated with PEPvIII-KLH loaded DCs (VICTORI Trial) 
with patients treated at Duke University with 81C6 anti-tenascin 131I labeled MAb.  Both patient populations had 
similar eligibility criteria. Published median survival fo r such patients treated with Gliadel™ is 59.6 weeks [ 1] and 
with concurrent RT and temozolomide is 58.4 weeks [ 2] 
7.3 Study Purpose/Rationale 
 
We have demonstrated in murine models that DCs loaded with tumor-specific antigens in the 
form of mRNA can induce potent an d specific humoral and cell-mediated immune responses that 
are effective against murine i.c. tumors, incl uding a syngeneic murine astrocytoma, without 
inducing autoimmunity [ 101, 104, 124 ]. Our previous clinical experience has also shown that DC 
vaccines in combination with standard of care ra diation therapy and chemotherapy are capable of 
generating potent, tumor-specific immune respons es and clinical radi ographic responses in 
patients with MGs. We and others have also shown that antigens derived from CMV  are 
contained within MGs and may serve as potent and specific immunotherapy targets. Vaccination 
and adoptive T cell strategies targeting CMV  in humans in other contexts, including the targeting 
of lesions within the CNS, have been safe and ef fective. We have also shown that DCs generated 
from patients with GBM and loaded with pp65- LAMP mRNA are capable  of generating CD4+ 
and CD8+ T cells that produce IFN-  and kill malignant astr ocytes infected with CMV  in an 
antigen-specific fashion. We have found that TILs isolated from these patients are significantly 
enriched for T cells th at specifically recognize CMV  antigens, suggesting that this response may 
be important in the biology of these tumors.  
 
CMV antigens have been identified in GBM and may make excellent antitumor 
immunotherapeutic targets. Vacc ination and adoptive T cell strate gies targeting CMV in humans 
in other contexts have been safe and effective.  DC vaccinations targeting other antigens in GBM 
have been safe and effective. Other peptid e vaccines given to patients with GBM during 
recovery from TMZ-induced lymphopenia ha ve produced potent tumor-specific immune 
responses. TMZ has recently shown modest efficacy, but is not curative, in some patients with 
newly-diagnosed GBM and is now frequently given to these patients during and after RT. 
Preclinical studies demonstrate that vaccine re sponses are enhanced during the recovery from 
TMZ-induced lymphopenia, but a preferen tial recovery of immunosuppressive T Regs during this 
homeostatic event likely serves to limit tumor-a ntigen directed immune responses. Preclinical 
studies have shown that unarmed antibodies sp ecific for the high affinity IL-2 receptor 
constitutively expressed on T Regs abrogate their immunosuppressive  phenotype and indirectly 
enhance effector T cell responsiveness. This is  consistent with the notion that the only non-
ELEVATE 
Version: [ADDRESS_896842] activated  T cell division in the absence 
of IL-2.  Basiliximab a chimeric (murine/human) monoclonal antibody (IgG 1K), produced by 
[CONTACT_12060], functions as an imm unosuppressive agent, specifically binding to 
and blocking the interleukin-2 receptor α-chain (IL-2R α, also known as CD25 antigen) on the 
surface of activated T-lymphocytes that ma y abrogate the functional recovery of T Regs in patients 
with GBM recovering from TMZ-induced ly mphopenia and enhance tumor-specific immune 
responses. 
 
DC vaccines have shown considerable promise in the treatment of cancer. However, generally <5% of injected DCs actually reach the vaccine-site draining lymph nodes, limiting the induction 
of anti-tumor immune responses. We conducted a clinical trial with newly-diagnosed GBM 
patients who were randomized to pre-immuniza tion with Td toxoid or unpulsed DCs before 
vaccination with CMV pp65 RNA-pulsed DCs  ( ATTAC Trial : FDA-IND-BB-[ZIP_CODE]). Strikingly, 
Td-treated patients had systemically enhanced DC migration and signifi cantly improved PFS and 
OS compared to controls (PFS >36.6 vs 4.4 months, OS >36.6 vs 11.6 months). Our murine studies corroborated that Td pr etreatment systemically enhan ced DC migration and suppressed 
tumor growth. In the proposed clinical st udy, we aim to: 1) enhance the migration of CMV  pp65 
RNA-pulsed DCs with Td, and 2) to evaluate th e effect of basiliximab and Td on survival 
outcomes when combined with DCs. 
  
ELEVATE 
Version: [ADDRESS_896843] of Td pre-
conditioning on progression-free 
survival among patients who are 
CMV negative Median progression-free survival from 
randomization See Section 15.6.3  
Exploratory To describe cha nges from baseline 
in immune response as measured by 
[CONTACT_20129]γ ELISpot Median change from baseline in 
ELISpot at each follow-up assessment See Section 15.7 
Exploratory To assess T cell polyfunctionality 
when ELISpot results are positive Proportion of patients with 1, 2 and 3 
functions at each assessment See Section 15.7 
Exploratory 
 To describe changes in T Regs over 
time Median  change from baseline in  T Reg 
levels  at each follow-up assessment See Section 15.7 
Exploratory To measure levels of CCL3 and 
other inflammatory  soluble factors Median change from baseline in CCL3 
and other inflammatory soluble factors. See Section 15.7 
9 INVESTIGATIONAL PLAN 
9.1 Study Design 
 
A maximum of 100 patients with resected, newl y-diagnosed WHO Grade IV glioma will be 
enrolled in this study with the expectation that  approximately 79 patients will be randomized to 
subsequent treatment after comple tion of radiation treatment with concurrent temozolomide.   At 
the time that accrual to Groups I and II are comple te an interim analysis will be conducted in 
order to make a decision concerning the accrual of additional patients to address efficacy 
objectives within patients subgroups defined by [CONTACT_622895] (see Section 15.8).  The study was 
ELEVATE 
Version: 20181120 
 
27 
 closed to enrollment in April 2018 (Amendment  73). All patients prev iously enrolled will 
continue on study as planned.  All enrolled patients will undergo a leukapheresis after resection for harvest of PBLs for 
generation of DCs. Patients will then receive approximately [ADDRESS_896844] targeted dose of 75 mg/m
2/d (please see Package Insert uploaded 
in eIRB for standard therapy). Pa tients should start RT within a pproximately [ADDRESS_896845] vaccination, are unable to tolerate TMZ, or 
whose DCs or PBLs fail to meet  release criteria will be withdrawn from the study and replaced  
and will not undergo repeat leukapheresis. For pa tients whose initial le ukapheresis yields less 
than 3 vaccines, repeat leukapheresis may be obt ained a minimum of 2 weeks from the previous 
leukapheresis (and may be repeated as needed ) if pre-pheresis blood work is within the 
Apheresis Center’s parameters and as long as this  does not cause a significant delay in treatment 
for the patient. At the post-RT clinic visit wher e patient’s MRI and blood work is evaluated prior 
to ordering the first post-RT cycle of TMZ, patients will be randomized to receive DC vaccination with one of three tr eating regimens: Group I: unpulsed DC pre-conditioning prior to 
vaccination #4; Group II: Td pre- conditioning prior to vaccination #4; or Group III: basiliximab 
infusions at vaccination #1 and #2 with Td pre- conditioning prior to v accination #4.  As of 
March 2017 (AMD 49), randomization of patients to  Group III has been terminated.  Please see 
Section 9.1.1  for a detailed outline of the randomi zation strategy for vaccine site pre-
conditioning and Section 9.1.7  for a detailed description of the double blinding process.   The 
study cycle of TMZ comprises a targeted dose of 150-200mg/m
2/d for 5 days every 5 (± 1) 
weeks. All patients will receive up to a total of 10 DC vaccines give n bilaterally at the groin site 
unless progression occurs. DC vaccines will be gi ven i.d. and divided equally to both inguinal 
regions. DC vaccines #1-3 will be given every tw o weeks, thus delaying the initiation of TMZ 
cycle 2 for all patients.  All remaining TMZ cycles  will continue every 5 (± 1) weeks. Before the 
first DC vaccination, patients will receive 0.5 mL  of Td (tetanus and diphtheria toxoids 
adsorbed) intramuscularly into the deltoid muscle  to ensure adequate immunity to the tetanus 
antigen. The Td vaccine will be obtained thr ough Duke Investigational Chemotherapy Services 
(ICS) Pharmacy. All patients wi ll undergo leukapheresis again for immunologic monitoring with 
specific assessment of baseline antigen-specific cellular and hu moral immune responses and 
further DC generations 4 ± 2 weeks after vaccine #3.  
 If the patient is determined to have progressi ve disease, the patient may be considered for 
eligibility on the INTERCEPT study (INTracere bral EGFR-vIII Chimeric Antigen Receptor 
Gene-Modified T Cells for PaTients with R ecurrent GBM, Pro00083828).  If the patient is 
determined to be eligible for the INTERCE PT study (Pro00083828), the cells extracted from 
leukapheresis while they were on this study, ELEVA TE, will be used to create the CAR T cells 
for administration in the INTERCEPT study.      
 
Group I Treatment Plan (DC Vaccinations with pr e-conditioning with Unpul sed DCs prior to the 
4th DC vaccine)  Patients in Group I will receive 1 x 106 autologous unpulsed DCs in saline 
administered to a single side of the groin, and 0.4  mLs of saline administered to the contralateral 
side one day prior to the fourth DC vaccine, which is always given bilaterally at the groin site.  
Patients will then receive 111In-labeled DCs as the 4th vaccine to compare the effects of different 
ELEVATE 
Version: [ADDRESS_896846]/CT imaging immediately and at 1 and 2 
days after injections. 
 
Group II Treatment Plan (DC Vaccinations with  pre-conditioning with Td prior to the 4th DC 
vaccine) 
Patients in Group II will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) 
administered to a single side of the groin, and 0.[ADDRESS_896847]/CT imaging immediately and at 1 and 2 
days after injection. 
 
Group III Treatment Plan (DC Vaccinations with basiliximab infusions prior to 1st and 2nd DC 
vaccine with Td pre-conditioning prior to 4th DC vaccine) 
Patients in Group III will receive the first 3 DC v accines every 2 weeks same as Groups I and II 
only they will also receive basiliximab 20 mg I. V. 7 days before DC vaccine # 1 and 7 days 
before DC vaccine # 2.  Prior to the 4th vaccine, patients will receive a single dose of Td toxoid 
(1 flocculation unit, Lf, in 0.4 mLs) administered  to a single side of the groin, and 0.4 mLs of 
saline administered to the contralateral side one  day prior to the fourth DC vaccine, which is 
always given bilaterally at th e groin site.  This group will not undergo migration studies. 
 
Effective March 2017 (AMD 49), randomization of patients to Group III has been terminated 
due to results from the related REGULA TE study (IRB # Pro00000581), a study that evaluated 
the safety, toxicity, and efficacy of T Reg inhibition with basiliximab.  REGULATE was used as 
the model for Group III in ELEVATE.  Recent an alyses of REGULATE data have shown that 
although the regulatory T cells we re depleted, the cells did no t show pp65 reactivity and their 
activation status was reduced.  Patients prev iously randomized to Group III will continue on 
study as planned.   
 
With AMD49, approximately [ADDRESS_896848] been  randomized to Groups I and II each in 
order to make a decision concerning the accrual of additional patients to address efficacy 
objectives within patient subgroups defined by [CONTACT_622895] (see Section 15.8). 
 
All Groups 
All patients will then be vaccinated in conjunc tion with subsequent TMZ cycles every 5 ± [ADDRESS_896849]. DCs will 
be given on day 21 ± [ADDRESS_896850] ic biopsy or resection. As this  is not a research procedure 
consent will be obtained separately. However, if tissue is obtained, it will be used to confirm 
ELEVATE 
Version: 20181120 
 
29 
 tumor progression histologically and to assess  immunologic cell infiltration and pp65 antigen 
escape at the tumor site. 
 
9.1.1 Randomization of Vaccine Site Pre-Conditioning Strategies 
A randomization will be performed to assign patients to one of the three treat ment strategies after 
completion of radiation with concurrent temozo lomide. A permuted block randomization scheme 
stratified by  [CONTACT_664104]: unpulsed DCs 
pre-conditioning prior to vaccination #4, Td pre-conditioning prior to  vaccination #4, or 
basiliximab infusions at vaccina tion #1 and #2 and Td pre-conditio ning prior to vaccination #4.  
 As previously noted, the randomization of subject s to Group III has been terminated as of AMD 
49.  With this amendment, the randomization scheme stratified by [CONTACT_664105]. 
 The administration of pre-conditioning agent (Td or unpulsed DCs) will be blinded for Groups I 
and II, however, the administration of the pre- conditioning agent (Td) and basiliximab for Group 
III will not be.  Hence, patients and providers will know when a patient has been assigned to the third treatment group (please see randomization and blinding SOP 18.2 in appendices). 
 
9.1.2 Definition of Unacceptable Toxicities 
Toxicities will be graded according to the NCI CTCAE version 4 criteria. An unacceptable 
toxicity is defined as any Grade 3 toxicity that is possibly, probably, or defi nitely attributed to a 
study agent (basiliximab, pre-c onditioning agent [Td or blinded Td/unpulsed DC], or pp65 DC 
vaccine) that does not resolve to baseline in 2-3 weeks, any Grade 3 hypersensitivity reactions or 
autoimmune toxicity requiring steroids or hormo ne replacement, any Grade 4 toxicity, including 
neurologic events not due to progressive disease, or any life–threatening ev ent not attributable to 
concomitant medication, co-morbid event, or di sease progression. A Grade 3 or greater toxicity 
that is clearly related to TMZ (an expected and known side effe ct) that does not resolve and 
requires an interruption, dose adjustment to me tronomic TMZ schedule, or  stoppage will result 
in subject removal from this protocol.   
9.1.[ADDRESS_896851]. 
 The study drug ( CMV pp65 RNA-pulsed DCs) dose will not be modified in this trial.  Those 
subjects whose cells fail to meet rele ase criteria will be removed and replaced. 
 
9.1.4 Safety Considerations 
Management of Toxicities 
If a Grade 3 NCI CTC or greater toxicity is s een that is not attribut able to a concomitant 
medication, co-morbid event, or disease progres sion that has been documented radiographically 
or clinically, the next immunization for that patien t will be withheld for up to 2 months or until 
the NCI CTC toxicity improves to a Grade 2 or un til the KPS score returns to within 10 points of 
baseline. However, planned procedures requirin g hospi[INVESTIGATOR_059], or long -term clinical decline 
that is now seen in patients y ears from WBRT, which are clearly  not related to study drug, but 
ELEVATE 
Version: [ADDRESS_896852] immunizations withheld. 
 
Adverse Event Reporting and Documentation 
An “Adverse Event” will be defined as any a dverse change from the subject’s pre-treatment 
baseline condition (which is assessed at the post -RT/TMZ clinic visit), in cluding any clinical or 
laboratory test abnormality that occurs duri ng the course of resear ch after the time of 
randomization. Adverse events will be categorized  and graded in accordance with the NCI CTC 
(Version 4). 
 
A “Serious Adverse Event” wi ll be defined as an undesira ble sign, symptom or medical 
condition which: 1) is fatal or  life threatening; 2)  requires inpatient hospi[INVESTIGATOR_26109] a 
prolongation of existing hospi[INVESTIGATOR_1916]; 3) results in pe rsistent or significant 
disability/incapacity; 4) c onstitutes a congenital anomaly or a birth defect and/or; 5) medically 
significant such that it may jeopardize the su bject, and may require medical or surgical 
intervention to prevent one of the outcomes listed above. 
 A summary of all adverse events (not just those considered rela ted to study drug) that occur 
following randomization will be kept which will categorize the event by [CONTACT_34565], 
relationship to treatment, its gr ade of severity, and resolution. Periodic review by [CONTACT_978] [INVESTIGATOR_664071]. If any such trends are 
identified, depending on their severity and freque ncy, a protocol amendment will be considered. 
 All adverse events which are se rious and unexpected should be reported immediately to [CONTACT_664135] (Pager: [PHONE_13733]) or her designee ( [PHONE_2319]) and to the FDA. Fatal or life-
threatening, unexpected adverse events will be re ported to the FDA by [CONTACT_756], facsimile, or in 
writing as soon as possible, but no later than [ADDRESS_896853] knowledge by [CONTACT_456].  All adverse events that are considered serious, unanticipated, and related or possibly related to 
the research (as defined by 21 CRF312.32[a]) will be reported to the Duke University Medical 
Center IRB using the appropriate  SAE report form. At the time of the annual progress report to 
the Duke University Medical Center IRB, a summa ry of the overall toxi city experience will be 
provided. 
 
9.1.5 Missed Doses 
To ensure that repetitive DC vaccines will be gi ven to patients, DCs will be given on day 21 ± [ADDRESS_896854] may be removed from the trial at the discretion of the study PI. 
ELEVATE 
Version: [ADDRESS_896855] and r ecorded at each study 
visit by [CONTACT_9137]. 
 
9.1.7 Study Drug(s) Blinding 
The Duke ICS Pharmacy will be responsible for the preparation of the Td and the saline used for 
the pre-conditioning done prior to the fourth vaccine.  The unpulsed DCs used for pre-conditioning will be prepared in the DBTIP Labora tory and delivered to the ICS for the labeling 
and distribution of the blinded pre-conditioning dr ugs (i.e., Td, unpulsed DCs, and saline).  Only 
those key personnel needed for th e preparation and distribution of the pre-conditioning drugs 
will be unblinded (i.e., ICS pharmacy staff and DBTIP Lab study drug manu facturing personnel, 
as well as the sta tisticians).  The patient and the remain ing key personnel (including the PI [INVESTIGATOR_664072]-conditioning  drugs) will be blinded to the pre-conditioning 
regimen.  Emergency unblinding pr ocedures are described in 13.3. 
 The administration of pre-conditioning agent (Td or unpulsed DCs) will be blinded for Groups I 
and II, however, the administration of the pre- conditioning agent (Td) and basiliximab for Group 
III will not be.  Hence, patients and providers will know when a patient has been assigned to the third treatment group (please see randomization and blinding SOP 18.2 in appendices). 
 
9.[ADDRESS_896856] of vaccine si te pre-conditioning with Td toxoid[ 125]. Patients randomized 
to Td showed increased dendritic cell migr ation bilaterally and significantly improved 
progression-free and overall survival. Furthermor e, we observed a modest association between 
effective DC migration to VDLNs and clinical outcomes. Based on the small sample size of the 
initial study, we would like to conduct a vali dation study with Td pre-conditioning that is 
powered sufficiently to evaluate the impact of DC migration on clinical outcomes. For that 
reason, we will conduct this validati on trial with identical Td formulation, doses, and DC vaccine 
treatment schedules as in the original study.  The 4th vaccine is the first monthly vaccine and we 
believe that the influence of the skin preconditioning would be most isolated at that time. In the 
original study, Td was used based on our mous e studies which revealed a memory CD4 T cell 
response to tetanus and unpulsed DC s were used based on research[ 126] that showed injection of 
DCs 24 hours before DC vaccine increased migrat ion. Therefore, 2 conditioning regimens were 
tested: Td versus unpulsed DCs with saline in the contralateral side as control.  
  
9.3 Rationale for Correlative Studies 
 
Please see Section 7.2 111Indium-labeling of Cells for in vivo Trafficking Studies.  
   
ELEVATE 
Version: [ADDRESS_896857] wi ll be considered “on st udy”. Rationale for taking 
patient off protocol treatment will be documented. 
9.5 Early Study Termination 
 
This study can be terminated at any time for any reason by [CONTACT_978]-sponsor . If this occurs, all 
subjects on study should be notified as soon as po ssible. Additional procedures and/or follow up 
should occur in accordance with Section 12.7. Section 12.6 describes procedur es and process for 
prematurely withdrawn patients. 
 
10 STUDY DRUG 
10.1 Names, Classification, an d Mechanism of Action 
 
Tetanus-diphtheria toxoid (Td toxoid adsorbed).  
 
Td is indicated for active booste r immunization against tetanus, diphtheria, and pertussis as a 
single dose; substitute 1-time dose of Tdap for Td  booster, then standard ly boost with Td every 
10 years. Please refer to section 7.2 on the use of Td in this protocol. 
 
DC vaccine 
 
Human CMV  pp65-LAMP mRNA-pulsed autologous DCs is the name [CONTACT_664131]. The name [CONTACT_664132] #4 will be 1 x 106 autologous 
unpulsed DCs or 1 Lf Td toxoid (depending on randomization). This vaccination will then 
consist of administration of 2 x 107 CMV  pp65-LAMP mRNA loaded mature DCs as described 
above except that these DCs will be labeled with 111In (50 μCi / 5 x 107 DCs) (Nycomed-
Amersham, Chicago, IL) prior to injection.  The cl ass of action for all stud y drugs is a biological 
with the exception of the tetanus toxoid, which is an antitoxin. 
 
Leukapheresis and dendritic cell vaccine generation  
 
At least two leukaphereses will be performed on each patient enrolled on this protocol. The 
leukapheresis will be used for DC generation and immunologic monitoring. All leukaphereses 
will be approximately a 4-hour leukapheresis. It is estimated that 10-12 L of blood will be 
processed during this leukapheresis. An additiona l 4-hour leukapheresis will be requested from 
patients with positive immunological responses to the therapy for additional immunologic 
monitoring studies or for patients who need add itional DCs generated to ensure a total of 10 
vaccines. 
 
ELEVATE 
Version: [ADDRESS_896858] leukapheresis in vitro  by 7-day culture with GM-CSF and 
IL-4. PBMC for in vitro  generation of DCs will be obtained by [CONTACT_664106]. For patien ts without sufficient 
venous access for leukapheresis a temporary intravenous catheter may be inserted. 
 
At the end of the 7 day incubation for generati on of DC a sample of the media is taken for 
mycoplasma testing, the cells are then harves ted and electroporated  with pp65-LAMP mRNA. 
The DCs are placed in a flask with  AIM V media GM-CSF + IL-4 + TNF- α + IL-6 + IL-1 β at 
37OC, 5% CO 2 for 18-20 hours for maturation. The cells ar e washed twice with PBS and frozen 
at 2-4 x 107cells/mL in 90% autologous  human AB serum (Valley Biomedical, Winchester, VA 
[ZIP_CODE]), 10% DMSO and 5% glucose in a co ntrolled-rate freezer at a rate of 1oC/minute.  
 
The DCs are then stored until needed at –135oC.  After freezing, an aliquo t of cells is thawed for 
QA/QC.  This testing will look at viability, (>70%) endotoxin content, (<5 E.U. /Kg B.W.) 
mycoplasma contamination (negative) and steril ity testing for aerobic a nd anaerobic bacterial 
cultures (1 x 106 DCs) and fungal cultures (1 x 106 DCs). 
 For each vaccination, cells that have pa ssed QA/QC will be rapi[INVESTIGATOR_179457] 37
oC, washed 
three times with PBS and counted. The cell c oncentration will be adjusted to 5 x 107 cells/mL 
and DCs will be resuspended in preservative fr ee saline and placed into a sterile tuberculin 
syringe with a 27 gauge needle.  For all DC preparations, including unlabeled DCs for vaccination and 
111In-labeled DCs, from 
the final preparation a sample of cells will be se nt for Gram stain and endotoxin testing prior to 
administration. DC vaccination will not be given until endotoxin testing has been passed (< 5.0 
E.U/Kg) and the Gram stain has been found to be ne gative. An aliquot of ce lls will also be sent 
for aerobic and anaerobic b acterial cultures (1 x 106 DCs) and fungal cultures (1 x 106 DCs). 
 
In the event of a positive sterility or mycoplasma test, the Principal Investigator [INVESTIGATOR_664073]. The FDA and IRB will be notified 
within 15 calendar days. The patient will be asked to be evaluated by a physician within 24 hours. If the patient has or develops a temperature >38.5 
oC or clinical evidence of infection at 
the injection site  (drainage, erythema or edem a) or systemically, the patient will have swabs 
taken from the injection sites (i f possible), along with blood, urine and sputum (if possible) sent 
for bacterial, fungal, and mycoplasmal culture and sensitivity testing.  The patient will be treated 
expectantly with antibiotics ba sed on the sensitivities of the organisms identified from the 
immunization product, and an independent infecti ous disease consultation will be obtained to 
guide further therapy. Any remaining immunization samples will be sent for sent for bacterial, 
fungal, and mycoplasmal culture and sens itivity testing and endotoxin testing, and 
immunizations will proceed only if the patient fu lly recovers and subsequent samples are found 
to be sterile.  If the patient is determined to have progressi ve disease, the patient may be considered for 
eligibility on the INTERCEPT study (INTracere bral EGFR-vIII Chimeric Antigen Receptor 
Gene-Modified T Cells for PaTients with R ecurrent GBM, Pro00083828).  If the patient is 
determined to be eligible for the INTERCE PT study (Pro00083828), the cells extracted from 
ELEVATE 
Version: 20181120 
 
34 
 leukapheresis while they were on this study, ELEVA TE, will be used to create the CAR T cells 
for administration in the INTERCEPT study. 
 
Basiliximab 
 
Because our Phase I study showed no differen ce between 20 and 40 mg of basiliximab in T Reg 
depletion, patients will receive basiliximab 20 mg  7 days before vaccines # 1 and # [ADDRESS_896859] by [CONTACT_664107] (K
a = 1 x 1010 
M-1) to the alpha chain of the high affinity IL -[ADDRESS_896860] kidney transpla ntation. Cumulative doses range d from 15 mg up to 150 mg. 
Peak mean ± SD serum concen tration following intravenous in fusion of 20 mg over 30 minutes 
is 7.1 ± 5.1 mg/L. There is a dose-proportional in crease in Cmax and AUC up to the highest 
tested single dose of 60 mg. The volume of distribution at steady state is 8.6 ± 4.[ADDRESS_896861] not been fully studied. The 
terminal half-life is 7.2 ± 3.2 days. Total body clear ance is 41 ± 19 mL/h. No clinically relevant 
influence of body weight or gender on distribut ion volume or clearance has been observed in 
adult patients. Elimination half-life was not infl uenced by [CONTACT_654] (20-69 years), gender or race.   
 
All patients will receive basili ximab mixed with 50-100 mLs of sterile 0.9% sodium chloride or 
dextrose 5% solution.  Basilixima b solution will be administered in  a peripheral or central vein 
over a 20-60-minute period.  When mixing the solution, gently invert  the bag in order to avoid 
foaming: do not shake. Infusion should be ad ministered intravenously immediately after 
preparation.  If it needs to be he ld longer, it should be refrigerated between 2° and 8°C (36° to 
46°F) for up to [ADDRESS_896862] sheet in the Appendix – Section 18.7. 
ELEVATE 
Version: 20181120 
 
35 
 10.2 Packaging and Labeling  of Study Agents 
 
 For CMV  pp65-LAMP mRNA-pulsed DCs: 
Name [CONTACT_664133]: pp65DCs Lot #: Lot 001 Caution New Drug Limited By [CONTACT_34541] 
 For autologous unpulsed DCs: 
Name [CONTACT_664133]: unpulsed DCs (blinded to personnel administering drug) Lot #: Lot 001 Caution New Drug Limited By [CONTACT_34541] 
 For tetanus diphtheria toxoid used in pre-conditioning 
Name 
[CONTACT_664133]: Td (blinded to personnel administering drug) Lot #: Lot 001 
 For CMV  pp65-LAMP mRNA loaded mature DCs labeled with 
111In (50 μCi / 5 x 107 
DCs) Name [CONTACT_664133]: Radiolabeled pp65DCs Lot #: Lot 001 Caution New Drug Limited By [CONTACT_34541] 
 For basiliximab: 
Name [CONTACT_664134]: basiliximab Lot #: Lot 001 
 Td™  (Tetanus diphtheria toxoid adsorbed); Stored at 4
oC used as Td booster vaccine 
Drug: Td Lot #  Expi[INVESTIGATOR_5952] 
10.3 Supply, Receipt, and Storage 
 
The DCs will be stored in a locked liquid nitr ogen freezer in the Molecu lar Products and Cellular 
Therapi[INVESTIGATOR_014] (MPACT) cGMP facility. The Nautilus LIMS (Laboratory Information Management 
System) database will track receipt and storage location. 
ELEVATE 
Version: [ADDRESS_896863] Facility Duke ICS Pharmacy Duke Radiopharmacy 
CMV  pp65-LAMP 
mRNA-pulsed DCs Td used for booster and for 
pre-conditioning CMV  pp65-LAMP 
mRNA loaded mature 
DCs labeled with 111In 
Unpulsed DCs Saline used for pre-
conditioning  
 Basiliximab  
 
10.4 Dispensing and Preparation 
 
The unblinded DC products (pp65 DC vaccines) w ill be delivered from the MPACT facility 
directly to the clinic under the supervision of the trained research staff. Each labeled patient 
vaccine will be transported to the clinic in a se parate cooler.  DCs will be administered according 
to protocol. The patient’s na me, Study ID, DOB, and Duke hi story number will be double 
verified prior to DC administration as is  standard Duke tran sfusion procedure.  
 The radiolabeled DC products used with the migr ation studies within Groups I and II will be 
prepared from the pp65 DC vaccines sent from the MPACT facility to the Radiopharmacy and 
dispensed radiolabeled fro m the Duke Radiopharmacy.  
  Please see Section 9.1.7  for blinding, preparing and dispensing the pre-conditioning study drugs 
(i.e., saline, Td, and unpulsed DCs).  Patients in Group III will receive basilixim ab from the Duke ICS Pharmacy.   
  
ELEVATE 
Version: [ADDRESS_896864] Facility Duke ICS Pharmacy Duke Radiopharmacy 
CMV  pp65-LAMP 
mRNA-pulsed DCs Td used for booster and for 
pre-conditioning (blinded 
for Groups I and II only) CMV  pp65-LAMP 
mRNA loaded mature 
DCs labeled with 111In 
 Saline used for pre-
conditioning (blinded)  
 Unpulsed DCs for pre-
conditioning (blinded)  
 Basiliximab  
 
10.[ADDRESS_896865] ELIGIBILITY 
 
Inclusion Criteria  
 Age ≥18 years of age. 
 WHO Grade IV Glioma with definitive res ection prior to consent, with residual 
radiographic contrast enhancing disease on th e post-operative CT or MRI of <[ADDRESS_896866].  
 MRI post RT does not show progressive  disease at time of randomization 
 Karnofsky Performance Status (KPS) of > 80%. 
 Hemoglobin ≥ 9.0 g/dl, ANC ≥ 1,500 cells/µl, platelets ≥ 125,000 cells/µl. 
 Serum creatinine ≤ 1.5 mg/dl, serum SGOT and bilirubin ≤ 1.5 times upper limit of normal. 
 Signed informed consent approved by [CONTACT_4707].  
 Female patients must not be pregnant or breast-feeding. Female patients of childbearing 
potential (defined as < [ADDRESS_896867] mens truation or not surgically sterile) must use a 
highly effective contraceptive method (allowed met hods of birth control, [i.e. with a failure 
rate of < 1% per year] are implants, injectable s, combined oral contraceptives, intra-uterine 
device [IUD; only hormonal], sexual abstinence or vasectomized partner) during the trial 
ELEVATE 
Version: 20181120 
 
38 
 and for a period of > [ADDRESS_896868] administration of trial drug(s). Female 
patients with an intact uterus (unless ame norrhea for the last 24 months) must have a 
negative serum pregnancy test within [ADDRESS_896869] study procedure 
(leukapheresis). 
 Fertile male patients must agree to use a highly effective contraceptive method (allowed 
methods of birth control [i.e. with a failure rate of < 1% per year] include a female partner 
using implants, injectables, combined oral  contraceptives, IUDs [only hormonal], sexual 
abstinence or prior vasectomy) during the tria l and for a period of > [ADDRESS_896870] administration of trial drugs. 
 
Exclusion Criteria: 
 Pregnant or breast-feeding. 
 Women of childbearing potential and men who are sexually active and not willing/able to 
use medically acceptable forms of contraception. 
 Patients with known potentially anaphylactic allergic reactions to gadolinium-DTPA. 
 Patients who cannot undergo MRI or SPECT due to obesity or to having certain metal in 
their bodies (specifically pacemakers, infu sion pumps, metal aneurysm clips, metal 
prostheses, joints, rods, or plates). 
 Patients with evidence of tumor in the brainste m, cerebellum, or spi[INVESTIGATOR_1831], radiological 
evidence of multifocal disease, or leptomeningeal disease. 
 Severe, active comorbidity, including any of the following: 
‐ Unstable angina and/or congestive h eart failure requiring hospi[INVESTIGATOR_059]; 
‐ Transmural myocardial infarcti on within the last 6 months; 
‐ Acute bacterial or fungal infection requiri ng intravenous antibiot ics at the time of 
study initiation; 
‐ Chronic obstructive pulmonary disease exa cerbation or other respi[INVESTIGATOR_664074]; 
‐ Known hepatic insufficiency resulting in clinical jaundice a nd/or coagulation 
defects; 
‐ Known HIV and Hepatitis C positive status; 
‐ Major medical illnesses or psychiatric impairments that, in the investigator's 
opi[INVESTIGATOR_1649], will prevent administration or completion of protocol therapy; 
‐ Active connective tissue disorders, such as lupus or scleroderma that, in the opi[INVESTIGATOR_379164], may put the patient  at high risk for radiation toxicity. 
 Co-medication that may interfere with study re sults; e.g. immuno-suppr essive agents other 
than corticosteroids. 
 Prior, unrelated malignancy requiring current active treatment with the exception of 
cervical carcinoma in situ and adequately trea ted basal cell or squamous cell carcinoma of 
the skin. (Treatment with tamoxifen or aromat ase inhibitors or other hormonal therapy that 
may be indicated in prevention of prior canc er disease recurrence, are not considered 
current active treatment.) 
 Patients are not permitted to have had any othe r conventional therapeutic intervention other 
than steroids prior to enrollment outside of  standard of care chemotherapy and radiation 
therapy.  Patients who receive previous i nguinal lymph node dissection, radiosurgery, 
brachytherapy, or radiolabeled monocl onal antibodies will be excluded. 
ELEVATE 
Version: 20181120 
 
39 
  Current, recent (within 4 weeks of the admi nistration of this study agent), or planned 
participation in an experimental drug study. 
 Known history of autoimmune disease (with  the exceptions of medically-controlled 
hypothyroidism and Type I Diabetes Mellitus). 
 
[ADDRESS_896871] of care.  A CMV  immune screen will also need to be drawn at one of these clinic 
visits following consent and prior to initiation of vaccine therapy. 
 
Initial clinical evaluations will also include  a baseline MMSE testing. A baseline and study 
eligibility MRI (with and without gadolinium enhan cement) of the brain per standard of care for 
comparison to subsequent MRI images will also be obtained.  The patient must have had a defi nitive resection.  Residual radi ographic contrast enhancement on 
post-resection CT or MRI must not exceed 1 cm in  diameter in any axial planes at time of 
consent.  Patients with progressive disease afte r radiation will not be a candidate for the vaccine 
despi[INVESTIGATOR_664075] d replaced (please see 
Section 12.7.4  for radiologic evaluations).  
 During collection of tumor sample at resection
 at Duke University, primary tissue will be banked 
and stored for IHC assays. Tissue will be stored in formalin-fixed blocks for subsequent partitioning of pathology slides. For initial rese ction at Duke, slides will be sent for MGMT 
promotor methylation status and IDH-1/2 mutati on analysis as part of the routine molecular 
diagnostic assay performed at Duke. If the surger y is performed outside of Duke and if such 
institutions do not incorporate th ese initial molecular diagnostic assays, slides from surgical 
blocks will be ordered for subs equent MGMT promoter methylat ion status and IDH-1/2 mutation 
analysis, so as to ensure baseline molecula r diagnostics of the tumor for each patient. 
 At the 
discretion of the study investigator , for surgical blocks containing initial resection and biopsy at 
recurrence (if applicable) tissue, formalin-fixed  paraffin-embedded slides will be requested for 
immunohistochemistry assays for the detection of CMV. These slides for CMV detection will 
not exceed 10% of the original specimen block, so  as to preserve adequate tissue should patients 
prefer future diagnostic studies. Patient consen t will be obtained for obtaining these slides in 
either scenario if a surgery/biops y was performed at Duke University  or at an external institution.  
ELEVATE 
Version: 20181120 
 
40 
  
If resection is done outside of  Duke University Hospi[INVESTIGATOR_307], formalin-fixed paraffin-embedded 
slides sectioned from outside blocks, not to ex ceed 10% of surgical specimen block tissue, 
prepared on Fischer Plus glass or Histostix coated slides when available will be mailed to: 
 Dina Randazzo, DO  Duke Brain Tumor Immunotherapy Program Department of Neurosurgery  The Preston Robert Tisch Br ain Tumor Center at Duke  
Box [ADDRESS_896872] blood samples 
taken for the following tests as required by [CONTACT_34548]: CBC, CMP, ionized 
Calcium, and β-HCG (for females of child-bearing poten tial). Total estimated blood volume 
required for these evaluations is 12-[ADDRESS_896873] 
leukapheresis will be approximately a 4-hour leuka pheresis, and it is estimated that 10-12 L of 
blood will be processed during this leukapheresis. On e red top tube will be obtained prior to each 
leukapheresis for immune monitoring (approximately 4 mLs). 
  
ELEVATE 
Version: 20181120 
 
41 
  
Table 4. Schedule of Events 
Appointment Time and 
Range Tumor 
Pathology1  Physical and 
Neurologic 
Exam 
KPS, MMSE2 MRI3 
 CMV 
Screen
4 CMP 
and  
CBC5 Blood for 
immunologic 
monitoring and 
Sub-clinical 
Autoimmunity6 
Screening and  
Pre-enrollment Prior to 
Consent X X X  X  
Consent Within 6 
weeks of OR    X X  
Leukapheresis7 After Consent     X X 
RT/TMZ Per SOC 
(starts within 6  weeks of OR)     X  
Post-RT TMZ 
cycle 1 Within 4 (±2) 
weeks of RT   X  X  
Basiliximab 
Infusion (Group III only) Day 14 (± 2 
days)  X   X X 
Td Booster IM Day 20 (± 2 
days) so long as before V#1       
Vaccine #1  Day 21 (± 2 
days)  X    X 
Basiliximab 
Infusion (Group III only) Day 28  (± 2 
days)  X   X X 
Vaccine #2 Day 35  (± 2 
days)  X     
Vaccine #3 Day 49  (± 2 
days)  X     
Leukapheresis 4 (± 2) weeks 
after V#[ADDRESS_896874] or MRI of <[ADDRESS_896875]. 
2 Clinical evaluations with each vaccine will include a general physical examination, complete neurologic examination, and KPS 
rating.  MMSE will be performed at baseline only.   
3 A baseline and study eligibility MRI (with and without gadolinium enhancement) of the brain per standard of care for compariso n 
to subsequent MRI images will also be obtained. MRI or contrast ed CT, every 8 ± [ADDRESS_896876] of care (may be 
adjusted by [CONTACT_34555]-oncologist).  
4 A CMV  immune screen will also need to be drawn at one of these clinic visits following consent and prior to initiation of vaccine 
therapy. 
5 CMP and CBC (with auto differential) to conf irm eligibility, and as per standard of care prior to and following surgery, and 
during SOC monthly and study cycles of TMZ and RT (if applicable). 
6 Blood work for immunologic monitoring will be drawn before each leukapheresis (1 red top only prior to phereses), basiliximab 
(Group III), on the day of vaccine #1 (9 yellow/2 red top only at this visit), and then prior to  each vaccine after vaccine #3 (9 
yellow/2 red top tubes) and/or at progression (whichever comes fi rst). For subjects who complete all [ADDRESS_896877] Duke Preston Rober t 
Tisch Brain Tumor Center visits and at pr ogression (whichever comes first). Periph eral blood for immunologic immune monitoring 
will be placed in 9 yellow tops and 2 red top tubes for a total of about 90 mLs and delivered to the BTIP lab for processing. P lasma 
from the yellow top tubes will be co llected at each time point listed where immunologic monitoring is done.  2 yellow and 1 red top 
tubes will be obtained at the pre-conditioning visit (all Groups) and at the SPEC/CT imaging visits (Groups I and II only).  Bl ood 
work for sub-clinical autoimmunity will be drawn before basi liximab (Group III), or vaccine #1 (all other groups), and repeated  
only if clinically indicated.  Laboratory evaluations to detect subclinical dise ase will be obtained as follows: serum thyroglobulin 
Ab (Lab Code 1802105), rheumatoid factor (Lab Code 5560195), an tinuclear Ab (Lab Code 5560214), Thyroid Profile (Lab Code 
1850277), and CMP (Lab Code 1004261). Total volume for s ub-clinical autoimmune testing is < [ADDRESS_896878] CBC, 
CMP, ionized Calcium, and βHCG within 48 hours prior to the procedure(s). Follow up leukapheresis will occur approximately 4 
± [ADDRESS_896879] immunization to obtain PBMCs for Immunologi c Monitoring and generation of additional DCs for continued 
vaccinations. Leukapheresis can be obtained up to every 2 weeks if needed accordi ng to the Duke Apheresi s Center protocol, but 
these will likely be needed less than ever y 2 months throughout the study to generate  enough DCs to continue  vaccinations. Bloo d 
for immune monitoring will  be drawn prior to each leukapheresis (1 red top tube – approximately 4 mLs). 
ELEVATE 
Version: 20181120 
 
42 
 Appointment Time and 
Range Tumor 
Pathology1  Physical and 
Neurologic 
Exam 
KPS, MMSE2 MRI3 
 CMV 
Screen
4 CMP 
and  
CBC5 Blood for 
immunologic 
monitoring and 
Sub-clinical 
Autoimmunity6 
TMZ Cycle 2 
(slight delay start) To start 
following V#3  X X  X  
Pre-conditioning8 1 day before 
V#4  X   X X 
Vaccine # 4 9 
(111In-labeled 
DCs) (Groups I & II only) Day 21(± 2 
days) of 
second cycle of TMZ      X 
Migration 
studies10  1 day and 2 
days after  V#4      X 
Vaccines with 
Cycles of TMZ11 On day 21 (± 2 
days) of each 
cycle of TMZ  X X  X X 
Monthly Vaccines 
After TMZ not to 
exceed 10 Every month 
(± 2 weeks)  X X  X X 
Progression12  X  X   X 
 
12.3 End of Treatment 
 
Vaccines are given as described above for a total of 10 or until progression (whichever comes first).  Once the vaccinations are complete, the tr eatment phase of the study will be over and the 
follow-up period will begin.  If the patient is determined to have progressi ve disease, the patient may be considered for 
eligibility on the INTERCEPT study (INTracere bral EGFR-vIII Chimeric Antigen Receptor 
Gene-Modified T Cells for PaTients with R ecurrent GBM, Pro00083828).  If the patient is 
determined to be eligible for the INTERCE PT study (Pro00083828), the cells extracted from 
leukapheresis while they were on this study, ELEVA TE, will be used to create the CAR T cells 
for administration in the INTERCEPT study. 
12.4 Follow-up Period 
 
Patients will be followed for survival, progressio n, and subsequent therapi[INVESTIGATOR_19081], and this data 
will be recorded by [CONTACT_5051].  For reco rding of subsequent therapi[INVESTIGATOR_014], the type of 
therapy(ies) that the subject r eceives will be recorded with appr oximate start and stop date, if 
                                                 
8  On day before the fourth DC vaccine, patients will receive vaccine site pre-conditioning strategy (Group I-unpulsed DCs i.d.;  
Group II and III- Td i.d.). A single dose of Td  toxoid (1 flocculation unit, Lf) or [ADDRESS_896880] of care blood for CBC and CMP will be drawn duri ng the pre-conditioning visit. 2 yellow and 1 red top tubes for 
immune monitoring will be obtained during the pr e-conditioning visit.  
9 At the day of the 4th vaccine (prior to administration), [ADDRESS_896881]/CT imaging immediately.  
[ADDRESS_896882]/CT imaging will be performed at 1 and 2 days after in jection of Vaccine #[ADDRESS_896883]/CT imaging visits 1 and 2 days after Vaccine #4, 2 yellow and 1 red top tubes for immune monitoring will be obtained 
only on patients randomized to Groups I and II (not Group III). 
[ADDRESS_896884] ereotactic biopsy or resection . 
As this is not a research proced ure consent will be obtained separately. However, if tissue is obtained, it will be used to con firm 
tumor progression histologically and to a ssess immunologic cell infiltration and pp65 antigen escape at the tumor site. 
ELEVATE 
Version: [ADDRESS_896885] progresses in  the follow-up period, blood 
for immunological monitoring will be drawn at the time of progression, if possible.     
12.5 End of Study 
 
Rationale for taking a patient off study will be documented (see section 12.6.1 ). In the Follow-up 
Period, patients will be followed for survival, pr ogression, and subsequent therapi[INVESTIGATOR_19081], and 
this data will be recorded by [CONTACT_5051]. 
12.[ADDRESS_896886](s) 
 
12.6.[ADDRESS_896887] from the study at any time based on hi s/her discretion. Reasons  for PI-initiated 
withdrawal may include, but ar e not limited to the following: 
 Inability to complete approximately [ADDRESS_896888] of care. 
 Inability to tolerate TMZ (either requiring a delay in cycles of TMZ, dose adjustment, or 
discontinuation). 
 Patients with an active infection requiring tr eatment or having an unexplained febrile 
illness (Tmax > 99.5° F). 
 Patients requiring an increase in corticosteroids, with the exception of nasal or inhaled 
steroid, such that at the time of first vacc ination they require a dose above physiologic 
levels, will be removed from the study and replaced.  For the purposes of this study, 
physiologic dose will be defined as <2 mg of dexamethasone / day. Once vaccinations have 
been initiated, if patients subsequently require increased steroids, they will still be permitted to remain on the study, but every effort will be made to minimize steroid requirements. 
 Adverse events 
 Abnormal laboratory values 
 Abnormal test procedure results (DCs fail to meet release crit eria; inability to tolerate 
leukapheresis) 
 Protocol deviation 
 Administrative issues 
 Disease progression 
 Pregnancy 
 
12.6.[ADDRESS_896889] to follow-up. 
 
ELEVATE 
Version: 20181120 
 
44 
 Subjects that received any basiliximab (Group III only) or va ccine therapy will be assessed and 
followed or adverse event monitoring/safety anal ysis for at least [ADDRESS_896890] 
vaccine (or basiliximab infu sion if in Group III).   
 
12.6.3  Replacement of Early Withdrawal(s) 
Subjects who voluntarily withdraw  prematurely or who are wit hdrawn by [CONTACT_978] [INVESTIGATOR_664076]. 
12.[ADDRESS_896891] and/or 
family at the screening visit and reviewed at  each study visit. This data may include the 
following: 
‐ All past medical a nd surgical history 
‐ Current medications  
‐ Changes in physical or neurologic symptoms 
‐ Any adverse events. 
‐  
12.7.2  Physical Exam 
Vital signs and physical and neurologic examinati ons will be assessed an d recorded along with a 
KPS score prior to enrollment and at each visit.  Curran Group Status will be performed at time 
of consent. Please see appendices – Section 18.[ADDRESS_896892]’s 
antihistamines to be held before and following vaccine administrations. 
 
12.7.[ADDRESS_896893] of care for 
eligibility and baseline measur ements, and to assess progressi on prior to vaccine therapy; 
although the purpose of this study is not to detect tumor res ponses, any evidence of tumor 
response will be determined according to th e Duke PRTBTC SOP (see Appendices – Section 
18.2). RANO criteria[ 127] will be used for overall assessment of tumor response and 
pseudoprogression.  Pseudoprogression by [CONTACT_664108]:  1) 
≥ 25% increase in the sum of the products of perpendicular diameters of enhancing lesions 
compared with the smallest tumor measurement obtained either at base line (if no decrease) or 
best response; 2) significant increase in T2/FLAIR non-enhanci ng lesion compared with baseline 
scan or best response af ter initiation of therapy  ‐ not caused by [CONTACT_186754] (eg, radiation 
therapy, demyelination, ischemic injury, infect ion, seizures, postoperativ e changes, or other 
treatment effects); 3) any new lesion; clear clinical deterioration not attributable to other causes 
apart from the tumor (eg, seizures, medication adverse effects, complications of therapy, 
cerebrovascular events, in fection, and so on); 4) failure to re turn for evaluation as a result of 
death or deteriorating condition. If pseudoprogression is suspected, the subject will continue with 
ELEVATE 
Version: [ADDRESS_896894]. 
 
12.7.5  Immunologic Assessments 
Immunological response evaluations  for baseline values will be conducted on the leukapheresis 
sample used to generate the DCs and on a s econd leukapheresis sample obtained 4 ± [ADDRESS_896895] immunization. Bl ood work for immunologic monito ring (9 yellow and 2 red top 
tubes) will be drawn before basiliximab (Gr oup III only), vaccine #1, and then as described 
above after vaccine #3 and/or at progression (whichever comes first) .  For subjects who complete 
all [ADDRESS_896896] Duke neuro-oncology visits and at 
progression (whichever comes first). The total amount of blood required for this purpose will be 
about 90 mLs. The immune monitoring blood drawn at vaccine #1 will be analyzed for baseline 
CCL3 level. Plasma from the yellow top tubes will be collected at each time point listed where 
immunologic monitoring is done.  Blood work for sub-clinical autoimmu nity will be drawn 
before basiliximab (Group III only ), or vaccine #1 (all other groups), and repeated only if 
clinically indicated. Laboratory evaluations to detect subclinical disease will be obtained as 
follows: serum thyroglobulin Ab (Lab Code  1802105), rheumatoid factor (Lab Code 5560195), 
antinuclear Ab (Lab Code 5560214), Thyroid Pr ofile (Lab Code 1850277), and CMP (Lab Code 
1004261). A comparison of pre-therapy lymphocyte f unctions to those at intervals after each 
immunization will be made. These tests may provide evidence for the development of immune responses following DCs immunization and will play an important role in the design of future 
DC-based clinical trials.  Ce llular immune responses to pp65 will be measured in a tiered 
approach. First, PBMCs will be assessed at pr e-treatment (leukapheresis) and during treatment 
for responses to pp65 using a qualified IFN-y ELI Spot.   If positive in the ELISPOT assay, pp65 
antigen-specific T cell response will be measured  by [CONTACT_593158] T cell assays using 8-[ADDRESS_896897] of treatment on cytokines and other solubl e factors will be assaye d in the serum/plasma. 
Serum/plasma will be measured to determine levels of CCL3 from the blood drawn at the 
vaccine #1 visit (in ALL Groups), and repeated at  the SPECT/CT imaging visits (2 yellow and 1 
red top tubes, in Gr oups I and II only). T
Reg kinetics will be measured by [CONTACT_2329] a constellation of 
markers specific for T Regs such as foxp3, CD25 and CD4. 
 In addition, blood and tumor samples will be stored  for possible future research in the Duke 
Brain Tumor Immunotherapy Program (DBTIP) Labor atory where all other samples from this 
study are stored.  The samples be ing stored are ONLY for this study.  Our mouse studies being 
done in the DBTIP Lab are identif ying markers that may influence migration, therefore, as other 
markers are identified, we would like to investig ate whether these same ma rkers are identified in 
human subjects enrolled on this trial. 
ELEVATE 
Version: 20181120 
 
46 
  
Gamma interferon-enzyme-linked immunospot (IFN- γ ELISpot) assay 
Using a tiered approach as described above, 90 mLs of peripheral blood will be drawn into (9 
yellow and 2 reds) vaccutainer tubes containi ng ACD.  PBMC will be separated by [CONTACT_664109].  Antigen specific T cell responses to pp65 will be measured ex vivo by [CONTACT_664110]- γ ELISpot assay. PBMCs at 2.5x10
5 per well will be stimulated 
overnight with a pool of synthetic peptide ( 15-mers overlappi[INVESTIGATOR_10373] 11 amino acids, JPT Peptide 
Technologies, [LOCATION_013]).  Single-use aliquots of the lyophilized pp65 pept ide pool will be resuspended to a final 
concentration of 1 μg/mL. Each assay will include test PBMC cultured with no peptide, pp65 
peptide pool, PHA (2.5 μg/mL), and positive and negative control PBMC wells for pp65 antigen. 
PBMCs from different visits for each patient will be batch analy zed on one plate.  PBMC added 
to duplicate wells of ELISpot assay plates  coated with mouse IgG1 anti-human IFN- γ mAb will 
be incubated overnight at 37°C, 5% CO
2, washed with PBS/Tween-20, incubated with 
biotinylated mouse IgG1 anti-human IFN- γ for 1 hour at room temperature, washed with PBS, 
incubated with avidin-peroxidase  complex for 1 hour at room te mperature, washed, incubated 
with substrate (3-amino-9-ethylcarbazole) fo r 4 minutes at room temperature and spot 
development will be stopped by [CONTACT_664111] e.  Spot enumeration by [CONTACT_664112] a Zeiss KS ELISpot system will be perfor med.  Results will be expressed as the mean 
SFC/[ADDRESS_896898]. Reap’s immunology laboratory on samples 
positive for secretion of IFN  by [CONTACT_664113]65. [CONTACT_664136]’s immunology 
laboratory conducts all the clinical immune mo nitoring for the Duke Brain Tumor Center. 
Polyfunctional T cell panels have been developed in our laborato ry and optimized for detection 
of CCL3 in T cells. This proce ss involves the rapid early detec tion and analysis of the production 
of TNF- a CCL3, IFN-  and IL-2 prior to cellular secretion following antigen-specific stimulation 
in vitro . The functional CD4 and CD8 immune response of the patients will be monitored using 
an 8 color assay.  Isolated PBMC will be stimulated for 6 hours with  the pool of 138 peptides spanning the entire 
pp65 gene. The cells will be stained for the surfa ce markers CD3 (to identify it as a T cell), CD4 
(to define as specific helper cell), CD8 (to de fine antigen specific cy totoxic T cells), CD27, 
CD28, CD45RO (to identify maturation and activati on state) and the intracel lular cytokines IL-2, 
TNF- a and IFN-. This procedure allows for the highly sensitive de tection of IFN- γ, TNF- a and 
IL-2-producing cells which are assumed to be sp ecifically responding to the stimulating antigen. 
This will also allow us to quantitate the change in antigen specific effector, central memory, and 
effector memory cells following each vaccinati on and monitor polyfuncti onal T cell responses.  
 
Serology/Multiplex Platform 
 
CCL3 and levels of other inflammatory solubl e factors may be assayed by [CONTACT_664114]. 
Antibody levels to the immunizing antigen may be measured. 
ELEVATE 
Version: [ADDRESS_896899] receiving any of the study drugs 
(basiliximab, Td or unpulsed DCs for pre-conditioning, 111In-labeled DCs, and pp65 DC 
vaccines) and which does not necessarily have a cau sal relationship with this  treatment. For this 
protocol, the definition of AE also includes wors ening of any pre-existing medical condition. An 
AE can therefore be any unfavorable and uninten ded or worsening sign  (including an abnormal 
laboratory finding), symptom, or disease temporally  associated with the us e of the DCs, whether 
or not related to use of the DCs. Abnormal la boratory findings without clinical significance  
(based on the PI’s judgment) shou ld not be recorded as AEs. Bu t laboratory value changes that 
require therapy or adjustment in prior therapy are considered adverse events. 
 From the time the subject is randomized through [ADDRESS_896900]’s last vaccine, all AEs 
must be recorded in the subject’s medical record and adverse events case report form. 
 AEs will be assessed according to the CTCAE ve rsion 4.0. If CTCAE grading does not exist for 
an AE, the severity of the AE will be graded as  mild (1), moderate (2), severe (3), life-
threatening (4), or fatal (5). 
 
Attribution of AEs will be indicated as follows: 
- Definite:  The AE is clearly related to the study drug - Probably:  The AE is likely related to the study drug - Possible:  The AE may be  related to the study drug 
- Unlikely:  The AE is doubtfully related to the study drug - Unrelated:  The AE is clearly  NOT related to the study drug 
 
13.1.1  Reporting of AEs 
A summary of all adverse events (not just thos e considered related to  the study drugs) will be 
kept which will categorize the event by [CONTACT_664115], relationship to which treatment, its grade 
of severity, and resolution. Pe riodic review by [CONTACT_978] [INVESTIGATOR_664077] e events will occur with the intention of 
identifying any trends or patterns in toxicity. If any su ch trends are identified, depending on their 
severity and frequency, a protocol amendment will be considered. 
13.2 Serious Adverse Events 
 
An AE is considered “serious” if in the opi[INVESTIGATOR_664078]: 
ELEVATE 
Version: 20181120 
 
48 
  Fatal 
 Life-threatening 
 Constitutes a congenital a nomaly or birth defect 
 A medically significant conditi on  (defined as an event that compromises subject 
safety or may require  
 medical or surgical intervention to prev ent one of the three outcomes above). 
 Requires inpatient hospi[INVESTIGATOR_103296] 
 Results in persistent or significant incap acity or substantial disruption to conduct 
normal life functions. 
 
13.2.[ADDRESS_896901]. Dina Randazzo (Pager: [PHONE_13733]) or her 
designee ([PHONE_2319]) and to the FDA. Fatal or  life-threatening, unexpected adverse events 
will be reported to the FDA by [CONTACT_94725], facsimile, or in writing as soon as possible, but no 
later than [ADDRESS_896902] knowledge by [CONTACT_456]. 
 All adverse events that are considered serious, unanticipated, and related or possibly related to 
the research (as defined by 21 CRF312.32[a]) will be reported to the Duke University Medical 
Center IRB and the FDA using th e appropriate SAE reporting proce ss. At the time of the annual 
progress report to the Duke Un iversity Medical Center IRB and the FDA, a summary of the 
overall toxicity experience will be provided. 
13.3 Emergency Unblinding of Investigational Treatment 
 
In the case of an allergic r eaction following the pre-conditioning part of the study, the research 
nurse administering the study drug(s) will alert th e PI (or her designate) for PI [INVESTIGATOR_664079]-
conditioning regimen the subject received.   [CONTACT_664137] (study PI) can be reached at  919-684-
5301  during regular business hours and at 919-97 0-9692 (or [PHONE_2319] for page office if 
designate) after hours and on weeke nds and holidays.  The ICS Ph armacy can be reached at 919-
668-0657.    
13.4 Safety Oversight Committee (SOC) 
 
The DCI SOC is responsible for annual da ta and safety monitoring of DUHS sponsor-
investigator phase I and II, ther apeutic interventional studies th at do not have an independent 
DSMB. The primary focus of the SOC is review of  safety data, toxiciti es and new information 
that may affect subject safety or efficacy. Annual safety reviews includes but may not be limited 
to review of safety data, enrollment status, stoppi[INVESTIGATOR_12596] , accrual, toxicities, 
reference literature, and interim analyses as provided by [CONTACT_456]-investigator. The SOC in 
concert with the DCI Mon itoring Team (see Section 14.1 for Monitoring Team description) 
oversees the conduct of DUHS cancer-related, spons or-investigator therapeutic intervention and 
prevention intervention studies th at do not have an external m onitoring plan, ensuring subject 
ELEVATE 
Version: [ADDRESS_896903] (DSMB) 
 
The Principal Investigator [INVESTIGATOR_34511]- Investigators must comply with applicable federal, state, and 
local regulations regarding reporting  and disclosure of conflict of interest. Conflicts of interest 
may arise from situations in which financial or other personal considerations have the potential 
to compromise or bias professiona l judgment and objectivity. Conflic ts of interest include but are 
not limited to royalty or consulting fees, sp eaking honoraria, advisory  board appointments, 
publicly-traded or privately-he ld equities, stock options, in tellectual property, and gifts. 
 The Duke University School of Medicine’s RIO reviews and manages res earch-related conflicts 
of interest. The Principal Inves tigator and Sub-Inves tigators must report c onflicts of interest 
annually and within [ADDRESS_896904] a documented 
management plan that is developed in conjunc tion with the Duke RIO and approved by [CONTACT_5040]/IEC.  Due to potential for COI in rela tion to proprietary interest in  the pp65CMV DC vaccine, a Data 
Safety and Monitoring Board (DSMBplus) has been  established.  Please see Appendix – Section 
18.[ADDRESS_896905] is enrolled, fo llowed by [CONTACT_12636] 1 – 3 
subjects until the study is closed to enrollm ent and subjects are no longer receiving study 
interventions that are more than minimal risk.   Additional monitoring may be prompted by [CONTACT_259495] m onitoring visits, unexpected 
frequency of serious and/or une xpected toxicities, or other co ncerns and may be initiated upon 
request of DUHS and DCI leadership, the DCI Cancer Protocol Committee, the SOC, the 
sponsor, the Principal Investigator, or the IRB.  All study documents must be made available 
upon request to the DCI Monitoring Team and othe r authorized regulatory authorities, including 
but not limited to the National Institute of Health, National Cancer Institute, and the FDA. Every reasonable effort will be made to mainta in confidentiality during study monitoring. 
14.[ADDRESS_896906] audits to evaluate  compliance with the 
protocol and the principles of GCP. The PI [INVESTIGATOR_664080](s) direct access to 
ELEVATE 
Version: 20181120 
 
50 
 all relevant documents and to allocate his/her ti me and the time of the study team to the CTQA 
auditor(s) in order to discuss fi ndings and any relevant issues. 
 CTQA audits are designed to protect the right s and well-being of huma n research subjects. 
CTQA audits may be routine or directed (for ca use). Routine audits are selected based upon risk 
metrics generally geared towards high subject enrollment, studies with limited oversight or 
monitoring, Investigator initiated Investigatio nal Drugs or Devices, federally-funded studies, 
high degree of risk  (based upon adverse events, type of study, or vulnerable populations), Phase 
I studies, or studies that involve  Medicare populations. Directed aud its occur at the directive of 
the IRB or an authorized  Institutional Official. 
 CTQA audits examine research studies/clinical  trials methodology, processes and systems to 
assess whether the research is conducted accord ing to the protocol approved by [CONTACT_12638]. 
The primary purpose of the audit/review is to ve rify that the standards for safety of human 
subjects in clinical trials and the quality of data produced by [CONTACT_12639]. 
The audit/review will serve as a quality assurance measure, internal to the institution. Additional 
goals of such audits are to detect both random and systemic errors occurring during the conduct 
of clinical research and to emphasize “best practi ces” in the research/clinical trials environment.
 
14.3 Data Management and Processing 
 
14.3.1  Study Documentation 
Study documentation includes but is not limited to source documents, case report forms, 
monitoring logs, appointment schedules, study te am correspondence with sponsors or regulatory 
bodies/committees, and regulatory documents that can be found in the DCI-mandated 
“Regulatory Binder”, which includes but is not limited to signed protocol and amendments, 
approved and signed informed consent forms,  FDA Form 1572, CAP and CLIA laboratory 
certifications, and clinical supplies receipts and distribution records. 
 Source documents are original records that cont ain source data, which is all information in 
original records of clin ical findings, observations, or other activities in a clinical trial necessary 
for the reconstruction and evaluation of the trial.  Source documents include but are not limited to 
hospi[INVESTIGATOR_1097], clinical and office charts, labo ratory notes, memoranda, subjects’ diaries or 
evaluation checklists, pharmacy dispensing records,  recorded data from automated instruments, 
copi[INVESTIGATOR_664081], microfiches, 
photographic negatives, microfilm or magnetic media,  x-rays, subject files, and records kept at 
the pharmacy, at the laboratories and at medico -technical departments in volved in the clinical 
trial. When possible, the original record should be retained as the source document. However, a 
photocopy is acceptable provided that it is a clear, legible, and an exact duplication of the 
original document. 
 
14.3.[ADDRESS_896907]’s medical records will be th e primary source document for the study. Source 
documents include all information in original reco rds and certified copi[INVESTIGATOR_2149], observations, or other activities in a clin ical investigation used for 
ELEVATE 
Version: 20181120 
 
51 
 reconstructing and evaluating the investigation.13 Source documentations may also include paper 
eligibility checklists, data flowsheets, patient reported outcomes and other paper documents. The 
PI, study coordinator, study research nurse, data management team and all associated study key 
personnel, are permitted to make entries, changes,  or corrections in the source documents or 
database per the study dele gation of authority log. 
 Errors on the source documents will be crossed out with a single line, and this line will not 
obscure the original entry. Changes or corrections will be dated, signed, initialed, and explained (if necessary). Database changes will be tracked via electronic trail automatically. 
 
14.3.3  Data Management Procedures and Data Verification 
The DCI IT Shared Resource has developed Title 21 CFR Part 11 compliant databases for cancer 
clinical trials. DCI IT has extensive expertise in database quality assurance, data standards, and 
use of caBIG tools to su pport cancer researchers.  
 Data queries will be generated automatically by [CONTACT_1624]. These data queries signify the presence of data inconsistencies. The study and data management team will cross-reference the 
data to verify accuracy. Missing or implausible data will be highlighted for the PI [INVESTIGATOR_664082] (i.e., conf irmation of data, correction of data, completion or confirmation 
that data is not available, etc.).  The database will be reviewed and discussed prio r to database closure, and will be closed only 
after resolution of all remaining queries. 
 
14.3.4  Coding 
All medical terms will be coded using CTCAE (version 4). 
 
14.3.5  Study Closure 
Following completion of the studies, the PI [INVESTIGATOR_664083] r ensuring the following 
activities:  
 Data clarification and/or resolution 
 Accounting, reconciliation, a nd destruction/return of used and unused study drugs 
 Review of site study r ecords for completeness 
 Shipment of all remaining laboratory samples to the designated laboratories 
[ADDRESS_896908] be approved by 
[CONTACT_664116]. 
                                                 
13 In 21 CFR 312.62(b), reference is made to records that are pa rt of case histories as “supporting data;” the ICH guidance for 
industry E6 Good Clinical Practice:  Consolidated Guidance (the ICH E6 guidance) (available at 
http://www.fda.gov/Drugs/GuidanceComplia nceRegulatoryInformation/Guidances/de fault.htm) uses the term “source 
data/documents.” For the purpose of this gui dance, these terms describe the same info rmation and have been used interchangeably . 
ELEVATE 
Version: [ADDRESS_896909] of car e radiotherapy with 
concurrent temozolomide, patients will be randomized to 1 of 3 treatment arms: 
 
 Group I will receive DC  vaccinations with unpulsed DC pre-conditioning  prior to the 
4th vaccination;  
 Group II will receive DC vaccinations with Td toxoid pre-conditioning  prior to the 4th 
vaccination; and 
 Group III will receive basiliximab infusions  prior to the 1st a nd 2nd DC vaccinations 
along with Td toxoid pre-conditioning prior to the 4th vaccination.   
 A permuted block randomization algorithm using a 1:1:[ADDRESS_896910] ratified by [CONTACT_622895] (positive, negative), 
with the assignment to arms I and II being double-blinded (See Sections 9.1.1  and 9.1.7  for 
further details).   The study was initially activated with Groups I a nd II.  However, approximately 2 months the 
study’s initial activation, the study has b een amended to include Group III.   
 Once accrual to Groups I and II are complete, a d ecision will be made co ncerning the accrual of 
additional patients to the Groups I and II in or der to assess the impact of Td toxoid pre-
conditioning within subgroups defined by [CONTACT_664117].   Options include continued accrual to 
both strata, accrual to only one stratum, or term ination of accrual.  Details are provided in 
Section 15.8.  
 Per Section 9.1, the study has been amended to terminat e randomization to Group III.  Rationale 
is provided in Section 9.1.  Though randomization to Group III has been terminated, the analyses 
proposed for Group III will still be done even t hough the power of planned analyses will be 
greatly reduced due to a sample size sma ller than anticipated within Group III. 
 The study was closed to enrollment in April 2018 (Amendment 73).  At the time the study was 
closed to new enrollment, a sufficient number of  subjects have been enrolled to power the 
migration endpoint described in Section 15.9.3 .  An interim analysis of survival was initially 
planned after 35 patients were randomized to each Arm A and Arm B (Section 15.8).  Survival 
analyses will still be conducted, but they may not be powered for the comparisons of survival 
described in Section 15.9.[ADDRESS_896911] to the availability of data, all randomized  patients will be included in all analyses of 
correlative and efficacy endpoints.   
ELEVATE 
Version: 20181120 
 
53 
 15.3 Patient Demographics and Ot her Baseline Characteristics 
 
Summaries of clinical and socio-demographic characteristics will be generated for all enrolled patients, as well as a summary stratified by [CONTACT_664118].  
Categorical descriptors will be summarized usi ng frequency distributions; whereas, interval 
variables will be summarized us ing percentiles, as well as m eans and standard deviations.  
15.4 Treatments 
 
A frequency distribution will be generated for the number of vaccines received among patients 
within each treatment arm.   
15.5 Primary Objectives 
 
This study has one key primary objective and three other primary objectives (See Section 8).  
The key primary objective is to assess the imp act of Td pre-conditioning with or without 
basiliximab on survival.  Other primary objectives include an examination of  the effect of pre-conditioning of the vaccine 
site with Td toxoid as opposed to unpulsed DCs at the time of the [ADDRESS_896912] of Td pre-conditioni ng within subgroups of patients defined by [CONTACT_664119] (negative/positive).   
 
15.5.1  Key Primary Objective:  Overall Survival 
The Kaplan-Meier estimator will be used to descri be the survival within each of the 3 treatment 
arms.  Median survival will be estimated within  each arm, with 95% confidence intervals.  OS 
will be defined as the time between randomization and death, or last follow-up if alive.  Two 
pairwise one-tailed log-rank te sts will be conducted to asse ss the impact of Td and/or 
basiliximab.  One test will compare the survival  experience of patients in the TD toxoid arm 
(Group II) and the unpulsed DC ar m (Group I), and the other test  will compare the survival 
experience within the basiliximab arm (Group III) and the unpulsed DC arm (Group I).  An 
intent-to-treat philosophy will be followed in these analyses.   
 
15.5.2  Other Primary Objective:  Migration  
Within Groups 1 and 2, the percentage of 111In-labeled DCs reaching inguinal nodes at 
vaccination #[ADDRESS_896913] will be used to compare assigned treatment groups 
(Groups I and II) with respect to migration.  This analysis will be based upon the first 12 patients 
within each arm (Groups I and II ) that receive vaccination #4. 
 
15.5.3  Other Primary Objective:  Survival Among CMV Positive Patients   
To assess the impact of Td pre-conditioning on survival among patients who are CMV positive, 
an analysis similar to those described for the key primary objective will be generated within the 
subgroup of patients who are CMV positive.  Specifically, the Kaplan-Meier estimator will be used to describe the survival among CMV positive  patients within Groups I and II.  Median 
survival will be estimated within each of these 2 treatment arms, with 95% confidence intervals.  
ELEVATE 
Version: [ADDRESS_896914] of pre-conditioning.  An intent-to-treat 
philosophy will be followed in these analyses.  Subgroup analyses will be underpowered and descrip tive unless a decision is made to continue 
accrual and treatment of CMV positive patients after the completion of accrual to Group III (See 
Section 15.8). 
 
15.5.4  Other Primary Objective:  Surviva l Among CMV Negative Patients   
Analyses similar to those described in section 15.5.[ADDRESS_896915] of Td pre-conditioning on progress -free survival within patient subgroups defined 
by [CONTACT_622895]. 
 
15.6.1  Key Secondary Objective:  PFS  
The Kaplan-Meier estimator will be used to descri be progression-free surviv al (PFS) within each 
arm.  Median PFS will be estimated within each of the 3 treatment arms, with 95% confidence 
intervals.  PFS will be defined as the time between randomization and initial failure (disease progression or death).  If the patient remain s alive without disease progression, PFS will be 
censored at the time of last follow-up.  Two pa irwise log-rank tests wi ll be conducted to assess 
the impact of Td and/or basiliximab.  One test will compare the PFS experience of patients in the 
TD toxoid arm (Group II) and the unpulsed DC arm (Group I), and the other test will compare 
the survival experience within the basilixima b arm (Group III) and the unpulsed DC arm (Group 
I).  An intent-to-treat philosophy wi ll be followed in these analyses. 
 
15.6.2  Other Secondary Objective:  PFS Among CMV Positive Patients   
To assess the impact of Td pre-conditioning on PFS among patients who are CMV positive, 
analysis similar to those described for the key primary objective will be generated within the subgroup of patients who are CMV positive.  Met hods similar to those described in Section 
15.5.3  will be used. 
 
15.6.3  Other Secondary Objective:  PFS Among CMV Negative Patients   
Analyses similar to those described in section 15.6.2  for patients who are CMV positive will be 
conducted among patients who are CMV negative. 
15.7 Exploratory Objectives 
 
Changes from baseline in immune response as m easured by [CONTACT_664120]-up assessment and within each treatment group.  Though analyses are exploratory, a Kruskal-Wallis will be used to compare trea tment groups relative to maximum changes in 
ELISpot observed.  A similar analysis will be conducted for levels of T
Reg, CCL3, and other 
ELEVATE 
Version: [ADDRESS_896916] 0 functions .  Within each treatment group, changes from 
baseline in the percentage of patients with 0, 1, 2 and 3 functions will be explored Hotelling’s T-
test or a nonparametric equivale nt.  Additional statistical analys es may be conducted to changes 
in polyfunctionality, as well as to  address other exploratory goals 
15.[ADDRESS_896917] of Td 
toxoid pre-conditioning within subgroups define d by [CONTACT_622895]. Based upon these analyses 
and other factors, one of 3 decisions will be made: 1) Continue accrual to both CMV positive and CMV negative strata within Groups I and II; 2)  Continue accrual to only one CMV stratum 
within Groups I and II; or 3) Terminate accrual to  all arms.  It should be noted that there are no 
options to continue accrual to Group III once the initial sample size goals are attained. 
 At the time that this interim analysis is c onducted, the number of deaths required per Section 
15.9.[ADDRESS_896918] 90% power to detect a hazard 
ratio of 0.5, 45 deaths need to be observe d within the two arms being compared. 
ELEVATE 
Version: [ADDRESS_896919] that accrual to  Group III was initiated a few months  after accrual was initiated on 
Groups I and II.    At the time that accrual to Groups I and II are completed, a decision will be made concerning the 
accrual of additional patients to  address efficacy questions within CMV subgroups (see Section 
15.8).  A priori sample size requirements for subgroups are described in Sections 15.9.4  and 
15.9.5 ; however, these calculations will be updated at the time of the interim analysis to reflect 
observed subgroup accrual rates.  At the time of  writing this protocol, we anticipate that a 
maximum of [ADDRESS_896920] 12 patients in Groups I and II will undergo migrati on studies are be used 
in those analyses. 
 
15.9.2  Key Primary Objective:  Survival  
The key primary goal of this study is to dete rmine whether the addition of either Td pre-
conditioning with vaccination #4 or basiliximab ad ministration with vaccin ation #1 and #[ADDRESS_896921]: 1) Td 
Toxoid arm (Group II) versus U npulsed DC arm (Group I), and; 2) Basiliximab arm (Group III) 
versus Unpulsed DC arm (Group I).  Though this phase II study is comparative, a false- positive rate of 0.[ADDRESS_896922] each 
hypothesis while maintaining reasonably high power[ 128-130 ].  This rate of false-positivity is 
used in lieu of a false positive rate of 0.[ADDRESS_896923] for there being multiple comparisons. 
ELEVATE 
Version: 20181120 
 
57 
  
Within the ATTAC study, the median survival in the DC vaccine arm without pulsed DC pre-conditioning was approximately 12 months; whereas , within the Td pre-conditioning arm median 
survival was estimated to be approximately [ADDRESS_896924] ratio of 
approximately 0.33.  Due to the small sample sizes in the ATTAC study, estimates are all 
associated with wide confidence intervals.  Gi ven these imprecise estimates and the potential for 
“regression to the mean” in this study replicat ing the ATTAC trial, we will target a smaller 
hazard ratio of 0.5 for a comparison of unpulsed DC (Group I) and Td (Group II).  With pi[INVESTIGATOR_664084] (Group III) and unpulsed DC (Group 
I), we will also target a hazard ratio of 0.[ADDRESS_896925] will be conducted at the 0.15 level of 
significance.  In order that each comparison will ha ve 90% power to detect a hazard ratio of 0.5, 
45 deaths need to be observed with in the two arms being compared[ 131].   
 We anticipate that patients will be accrued at the rate of 4 patients per month, with a randomization rate of 3.5 patients per month.  As described earlier, the protocol was initially 
activated with only Groups I and II.  Howeve r, with a later amendment, patients will be 
randomized to one of 3 arms.  In the following calc ulations, we will assume that there is a period 
of 2 months during which patients are randomized to  one of 2 arms after which patients will be 
randomized to one of 3 arms.  Tabulated below is the anticipated accrual and randomization rate 
within each arm during each period of accrual. 
 
Table 5. Anticipated Accrual  and Randomization Rates 
# of Arms Accruing Accrual Rate 
(Patients / Month / Arm) Randomization Rate 
(Patients / Month / Arm) 
[ADDRESS_896926] patient ra ndomization to observe 45 events[ 132-134 ]. 
 In addition to the comparison of Groups I and II, we plan to compare the survival of patients 
enrolled on Arms I and III.  Under the null hypothesis, approximately [ADDRESS_896927] patient randomizati on is required to observe 45 events. 
 
15.9.3  Other Primary Objective:  Migration  
One goal of this study is to validate observati ons made in the recently completed ATTAC trial 
concerning Td toxoid pre-conditioning.  The design of  this study (Groups I a nd II) is identical to 
ELEVATE 
Version: [ADDRESS_896928] by 
[CONTACT_664121] (temozolomide + XRT) and then by [ADDRESS_896929] (also the Mann-Whitney U test) to have 95% 
power to detect a difference similar to that observed in the ATTAC study.  Re-sampling with 
replacement from the pi[INVESTIGATOR_664085] 10,000 bootstrappi[INVESTIGATOR_664086]. 
 With 12 patients in the Td toxoid arm (Group I) and 12 patients in the unpulsed DC arm (Group 
II) who have undergone migration studies at vaccin ation #4, simulations show that there is 95% 
power to detect the difference observed in the ATTAC trial assuming α=0.05. 
 
15.9.4  Other Primary Objective:  Survival Among CMV Positive Patients   
One of the other primary goals of this study is  to determine whether Td pre-conditioning at 
vaccination #4 in conjunction with DC vaccination  and temozolomide is worthy of investigation 
in a large phase III study am ong patients who are CMV positive.  That assessment involves a 
comparison of survival in Groups I and II among patients who are CMV positive.  The sample size requirements needed to address this subgroup question are similar to those 
described for the key primary objective (Section 15.9.2 ).  A 1-tailed logrank test will be 
conducted at the 0.[ADDRESS_896930] 90% power to dete ct a hazard ratio of 0.5, 
45 deaths need to be observed with in the two arms being compared[ 131].   
 As described in section 15.9.2 , we anticipate that patients will be  accrued to the study at the rate 
of 4 patients per month, with a randomization rate of 3.5 patients per month.  We also anticipate 
that approximately 50% of patients will be CMV positive.  As described in Section 15.9.2 , the study will randomize patients to one of two arms, and after 
amendment, it will randomize patients to one of 3 arms.  If a decision is made to continue patient 
accrual (See Section 15.8), the study will randomize patients to either Group I or II.  Tabulated 
below is the anticipated accr ual and randomization rate for CMV positive patients within each 
arm during each period of accrual. 
 
Table 6. Anticipated Accrual and Randomiz ation Rate for CMV Positive Patients 
# of Arms Accruing Accrual Rate 
(Patients / Month / Arm) Randomization Rate 
(Patients / Month / Arm) 
[ADDRESS_896931] been accrued, with half being assigned to Group I and half to Group II.  If accrual to 
ELEVATE 
Version: [ADDRESS_896932] of the 
study and accrual is extended for CMV positive pa tients, approximately 57 months would be 
required to address this subgr oup objective.  The 57 months assumes 2 months of 2-arm 
randomization, 27 months of 3-arm randomizati on, 16 months of expanded subgroup accrual, 
and 12 months of follow-up. 
 
15.9.5  Other Primary Objective:  Surviva l Among CMV Negative Patients   
The final other primary goals of this study is to determine whether Td pre-conditioning at 
vaccination #4 in conjunction with DC vaccination  and temozolomide is worthy of investigation 
in a large phase III study am ong patients who are CMV negative.  That assessment involves a 
comparison of survival in Groups I and II among  patients who are CMV negative.  The sample 
size requirements needed to addres s this subgroup question are id entical to those described in 
section 15.9.4  given that the prevalence of CMV ne gative is anticipated  to be 50%.   
 
[ADDRESS_896933] research design or  data analysis (i.e. 
amendments affecting subject population, inclusion/exclusion cr iteria, agent administration, 
statistical analysis, etc.).  The Principal Investigator [INVESTIGATOR_12604]-approval from the IRB within [ADDRESS_896934] enrollment. 
ELEVATE 
Version: [ADDRESS_896935]’s study records, and a copy of the informed  consent form will be provided to the subject. 
The Principal Investigator [INVESTIGATOR_664087]/her primary care physic ian about participation in the study. If the subject agrees to 
such notification, the Pr incipal Investigator will inform th e subject’s primary care physician 
about the subject’s particip ation in the clinical study. 
16.[ADDRESS_896936]’s 
data will be maintained. RDSPs will be appr oved by [CONTACT_12644].  To protect privacy, every reasonable effort w ill be made to prevent undue access to subjects 
during the course of the study. Pros pective participants will be consented in an exam room where 
it is just the research staff, the patient and his fa mily, if desired. For all future visits, interactions 
with research staff (study doctor and study coordi nators) regarding resear ch activities will take 
place in a private exam room. All research related inte ractions with the participant will be 
conducted by [CONTACT_664122].  To protect confidentiality, subject files in paper format will be  stored in secure cabinets under 
lock and key accessible only by [CONTACT_664123]. Subjects will be identified only by a unique 
study number and subject initials. Electronic records of subject data will be maintained using an 
Oracle Clinical database, which is housed by [CONTACT_3433] e DCI. Access to electronic databases will be 
limited to the Principal Investig ator, key personnel, statistician s, the Radiolabeled Pharmacy 
personnel, and the PRTBTC data manager. Data stored on portable memory devices will be de-
identified. The security and viability of the IT infrastructure will be managed by [CONTACT_33678]/or 
Duke Medicine.   Upon completion of the study, res earch records will be  archived and handled per DUHS HRPP 
policy.  
ELEVATE 
Version: [ADDRESS_896937] names or identifiers will not be used in reports, presentations at scientific meetings, or 
publications in scientific journals. 
16.5 Data and Safety Monitoring 
 
Data and Safety Monitoring will be performed in accordance with the DCI Data and Safety 
Monitoring Plan. For a more detailed  description of the DSMP for th is protocol, refer to attached 
plan in Appendices (Section 18.5). 
16.[ADDRESS_896938] research desi gn or data analysis (i.e., amendm ents affecting subject population, 
inclusion/exclusion criteria, agent administration, etc.). 
16.7 Records Retention 
 
The Principal Investigator [INVESTIGATOR_12608]-re lated records for the longer of a period of: 
‐ at least two years after the date on whic h a New Drug Application is approved by [CONTACT_1556] 
‐ at least two years afte r formal withdrawal of the IND associated with this protocol 
‐ at least six years after st udy completion (Duke policy). 
16.[ADDRESS_896939] appointments, 
publicly-traded or privat ely-held equities, stock options, intellectual property, and gifts. 
 The Duke University School of Medicine’s RIO reviews and manages res earch-related conflicts 
of interest. The Principal Inves tigator and Sub-Inves tigators must report c onflicts of interest 
annually and within [ADDRESS_896940] a documented 
management plan that is developed in conjunc tion with the Duke RIO and approved by [CONTACT_5040]/IEC.  
16.9 Registration Procedure 
 
ELEVATE 
Version: [ADDRESS_896941]’s visits associat ed in the Duke Epic Maestro Care system with 
this protocol which is ente red after Duke IRB approval. 
 
  
ELEVATE 
Version: 20181120 
 
63 
 17 REFERENCES 
 
1. Westphal, M., et al., A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers 
(Gliadel wafers) in patients with primary malignant glioma.  Neuro-oncology, 2003. 5: p. 79-88. 
2. Stupp, R., et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.  New 
England Journal of Medicine., 2005. 352(10): p. 987-996. 
3. Kelly, P.J., Stereotactic resection and its limitations in glial neoplasms.  Stereotact Funct Neurosurg, 1992. 
59(1-4): p. 84-91. 
4. Walker, M.D., et al., Randomized comparisons of radiotherapy and nitrosoureas for the treatment of 
malignant glioma after surgery.  N Engl J Med, 1980. 303(23): p. 1323-1329. 
5. Stupp, R., et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.  N Engl J 
Med, 2005. 352(10): p. 987-996. 
6. Walker, M.D., et al., Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A 
cooperative clinical trial.  J Neurosurg, 1978. 49(3): p. 333-343. 
7. Shapi[INVESTIGATOR_2152], W.R., Therapy of adult malignant brain tumors: what have the clinical trials taught us?.  Semin 
Oncol, 1986. 13(1): p. 38-45. 
8. Salford, L.G., A. Brun, and S. Nirfalk, Ten-year survival among patients with supratentorial astrocytomas 
grade III and IV.  J Neurosurg, 1988. 69(4): p. 506-509. 
9. Dinapoli, R.P., et al., Phase III comparative evaluation of PCNU and carmustine combined with radiation 
therapy for high-grade glioma.  J Clin Oncol, 1993. 11(7): p. 1316-1321. 
10. Pi[INVESTIGATOR_19323], J.D., et al., Steps towards cost-benefit analysis of regional neurosurgical care.  Br Med J, 1990. 
301(6753): p. 629-635. 
11. Ekman, M. and M. Westphal, Cost of brain tumour in Europe.  Eur J Neurol, 2005. 12: p. 45-9. 
12. Imperato, J.P., N.A. Paleologos, and N.A. Vick, Effects of treatment on long-term survivors with malignant 
astrocytomas.  Ann Neurol, 1990. 28(6): p. 818-822. 
13. Hall, W.A. and O. Fodstad, Immunotoxins and central nervous system neoplasia.  J Neurosurg, 1992. 76(1): 
p. 1-12. 
14. Banchereau, J. and R.M. Steinman, Dendritic cells and the control of immunity.  Nature, 1998. 392(6673): 
p. 245-52. 
15. Steinman, R.M., Dendritic cells and the control of immunity: enhancing the efficiency of antigen 
presentation.  Mount Sinai Journal of Medicine, 2001. 68(3): p. 106-66. 
16. Fujii, S., et al., Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic 
cells following autologous peripheral blood stem cell transplantation.  Japanese Journal of Cancer 
Research, 1999. 90(10): p. 1117-29. 
17. Heiser, A., et al., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL 
responses against metastatic prostate tumors.  Journal of Clinical Investigation., 2002. 109(3): p. 409-17. 
18. Su, Z., et al., Immunological and clinical responses in metastatic renal cancer patients vaccinated with 
tumor RNA-transfected dendritic cells.  Cancer Research, 2003. 63(9): p. 2127-33. 
19. Holtl, L., et al., Cellular and humoral immune responses in patients with metastatic renal cell carcinoma 
after vaccination with antigen pulsed dendritic cells.  Journal of Urology, 1999. 161(3): p. 777-82. 
20. Lodge, P.A., et al., Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase 
II clinical trial.  Cancer Research, 2000. 60(4): p. 829-33. 
21. Lim, S.H. and R. Bailey-Wood, Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.  
International Journal of Cancer, 1999. 83(2): p. 215-22. 
22. Hsu, F.J., et al., Vaccination of patients with B-cell lympoma using autologous antigen-pulsed dendritic 
cells.  Nature Medicine, 1996. 2: p. 52-58. 
23. Murphy, G.P., et al., Higher-dose and less frequent dendritic cell infusions with PSMA peptides in 
hormone-refractory metastatic prostate cancer patients.  Prostate, 2000. 43(1): p. 59-62. 
24. Morse, M.A., et al., A Phase I study of active immunotherapy with carcinoembryonic antigen peptide 
(CAP-1)-pulsed, autologous human cultured dendritic  cells in patients with metastatic malignancies 
expressing carcinoembryonic antigen.  Clinical Cancer Research, 1999. 5(6): p. 1331-8. 
25. Tjoa, B.A., et al., Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA 
peptides.  Prostate, 1998. 36(1): p. 39-44. 
ELEVATE 
Version: 20181120 
 
64 
 26. Thurner, B., et al., Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells 
expands specific cytotoxic T cells and induces regressi on of some metastases in advanced stage IV 
melanoma.  Journal of Experimental Medicine, 1999. 190(11): p. 1669-78. 
27. Schuler-Thurner, B., et al., Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in 
terminal stage HLA-A2.1+ melanoma patients by [CONTACT_179509]-derived dendritic cells.  Journal of 
Immunology, 2000. 165(6): p. 3492-6. 
28. Salgaller, M.L., et al., Dendritic cell-based immunotherapy of prostate cancer.  Critical Reviews in 
Immunology, 1998. 18(1-2): p. 109-19. 
29. Salgaller, M.L., et al., Report of immune monitoring of prostate cancer patients undergoing T-cell therapy 
using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen 
(PSMA).  Prostate, 1998. 35(2): p. 144-51. 
30. Rieser, C., et al., Mature dendritic cells induce T-helper type -1-dominant immune responses in patients 
with metastatic renal cell carcinoma.  Urologia Internationalis, 2000. 63(3): p. 151-9. 
31. Nestle, F.O., et al., Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.  
Nature Medicine, 1998. 4(3): p. 328-32. 
32. Murphy, G., et al., Phase I clinical trial: T-cell therapy for pros tate cancer using autologous dendritic cells 
pulsed with HLA-A0201-specific peptides fr om prostate-specific membrane antigen.  Prostate, 1996. 29(6): 
p. 371-80. 
33. Vancikova, Z. and P. Dvorak, Cytomegalovirus infection in immunocompetent and immunocompromised 
individuals--a review.  Current Drug Targets Immune Endocrine & Metabolic Disorders, 2001. 1(2): p. 179-
87. 
34. Rafferty, K.A., Jr., Herpes viruses and cancer.  Scientific American, 1973. 229(4): p. 26-33. 
35. Kadow, J.F., A. Regueiro-Ren, and S.P. Weinheimer, The role of viruses in human cancer development and 
antiviral approaches for intervention.  Current Opi[INVESTIGATOR_179467], 2002. 3(11): p. 1574-9. 
36. Harkins, L., et al., Specific localisation of human cytomegalovirus nucleic acids and proteins in human 
colorectal cancer.  Lancet, 2002. 360(9345): p. 1557-63. 
37. Samanta, M., et al., High prevalence of human cytomegalovirus in prostatic intraepi[INVESTIGATOR_664088].  Journal of Urology, 2003. 170(3): p. 998-1002. 
38. Cobbs, C.S., et al., Human cytomegalovirus infection and expression in human malignant glioma.  Cancer 
Research, 2002. 62(12): p. 3347-50. 
39. Riddell, S.R. and P.D. Greenberg, Cellular adoptive immunotherapy after bone marrow transplantation.  
Cancer Treatment & Research, 1995. 76: p. 337-69. 
40. Walter, E.A., et al., Reconstitution of cellular immunity against cytomegalovirus in recipi[INVESTIGATOR_505485] T-cell clones from the donor.  New England Journal of Medicine, 1995. 
333(16): p. 1038-44. 
41. Paar, D.P. and R.B. Pollard, Immunotherapy of CMV infections.  Advances in Experimental Medicine & 
Biology., 1996. 394: p. 145-51. 
42. Dazzi, F. and J.M. Goldman, Adoptive immunotherapy following allogeneic bone marrow transplantation.  
Annual Review of Medicine, 1998. 49: p. 329-40. 
43. Bigger, J.E., et al., Protection against murine cytomegalovirus retinitis by [CONTACT_570082]-
specific CD8+ T cells.  Investigative Ophthalmology & Visual Science, 1999. 40(11): p. 2608-13. 
44. Numazaki, K., et al., Adoptive immunotherapy for interstitial pneumonia associated with cytomegalovirus 
infection.  Clinical Infectious Diseases, 1997. 25(5): p. 1246-7. 
45. Papadopoulos, E.B., et al., Infusions Of Donor Leukocytes To Treat Epstein-Barr Virus-Associated 
Lymphoproliferative Disorders After Alloge neic Bone Marrow Transplantation.  New England Journal of 
Medicine, 1994. 330(17): p. 1185-1191. 
46. Emanuel, D.J., Uses of immunotherapy for control of human cytomegalovirus-associated diseases.  
Transplantation Proceedings., 1991. 23([ADDRESS_896942] 3): p. 144-6. 
47. Emanuel, D.J., et al., Treatment of posttransplant lymphoproliferative disease in the central nervous system 
of a lung transplant recipi[INVESTIGATOR_179469].  Transplantation, 1997. 63(11): p. 1691-4. 
48. Liu, Z., et al., Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the pr evention and treatment 
of EBV-associated post-transplant lymphomas.  Recent Results Cancer Research, 2002. 159: p. 123-33. 
49. Lucas, K.G. and J.C. Barrett, Adoptive immunotherapy for EBV-associated malignancies.  Cancer Treat 
Research, 1999. 101: p. 203-32. 
50. Rooney, C.M., et al., Infusion of cytotoxic T cells for the preven tion and treatment of  Epstein-Barr virus-
induced lymphoma in allogeneic transplant recipi[INVESTIGATOR_840].  Blood, 1998. 92(5): p. 1549-55. 
ELEVATE 
Version: 20181120 
 
65 
 51. Koutsky, L.A., et al., A Controlled Trial of a Human Papi[INVESTIGATOR_133900] 16 Vaccine.  New England 
Journal of Medicine, 2002. 347(21): p. 1645-1651. 
52. Kondo, K. and E.S. Mocarski, Cytomegalovirus latency and latency-specific transcription in hematopoietic 
progenitors.  Scand J Infect Dis Suppl, 1995. 99: p. 63-7. 
53. Prosch, S., et al., Human cytomegalovirus reactivation in bone-marrow-derived granulocyte/monocyte 
progenitor cells and mature monocytes.  Intervirology, 1999. 42(5-6): p. 308-13. 
54. Reeves, M.B., et al., Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the 
dendritic cells of healthy carriers.  Proc Natl Acad Sci U S A, 2005. 102(11): p. 4140-5. 
55. Larsson, S., et al., Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all 
seropositive and most seronegative healthy blood donors over time.  Transfusion, 1998. 38(3): p. 271-8. 
56. Sissons, J.G., J.H. Sinclair, and L.K. Borysiewicz, Pathogenesis of human cytomegalovirus disease and the 
kidney.  Kidney Int Suppl, 1991. 35: p. S8-12. 
57. Plotkin, S.A., et al., Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal 
transplant recipi[INVESTIGATOR_840].  Transplantation, 1994. 58(11): p. 1176-8. 
58. BenMohamed, L., et al., Intranasal administration of a synthetic lipopeptide without adjuvant induces 
systemic immune responses.  Immunology, 2002. 106(1): p. 113-21. 
59. Pepperl-Klindworth, S., N. Frankenberg, and B. Plachter, Development of novel va ccine strategies against 
human cytomegalovirus infection based on subviral particles.  Journal of Clinical Virology, 2002. [ADDRESS_896943] 
2: p. S75-85. 
60. Britt, W., et al., Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice.  
Journal of Infectious Diseases, 1995. 171(1): p. 18-25. 
61. Gonczol, E., et al., Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-
passage strain.  Journal of Infectious Diseases, 1989. 159(5): p. 851-9. 
62. Minamishima, Y., Immunoprophylaxis of experimental cytomegalovirus infection.  Annales de 
Microbiologie (Paris), 1977. 128(3): p. 399-407. 
63. Morello, C.S., M. Ye, and D.H. Spector, Development of a vaccine against murine cytomegalovirus 
(MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete 
protection against viral replication.  Journal of Virology, 2002. 76(10): p. 4822-35. 
64. Cicin-Sain, L., et al., Vaccination of mice with bacteria carrying a cloned herpesvirus genome 
reconstituted in vivo.  Journal of Virology, 2003. 77(15): p. 8249-55. 
65. Adler, S.P., et al., Guinea pig and human cytomegaloviruses do not share cross-reactive neutralizing 
epi[INVESTIGATOR_322].  Journal of Medical Virology, 1995. 47(1): p. 48-51. 
66. Adler, S.P., et al., Safety and immunogenicity of the Towne strain cytomegalovirus vaccine.  Pediatric 
Infectious Disease Journal, 1998. 17(3): p. 200-6. 
67. Sachs, G.W., R.L. Simmons, and H.H. Balfour, Jr., Cytomegalovirus vaccine: persistence of humoral 
immunity following immunization of renal transplant candidates.  Vaccine, 1984. 2(3): p. 215-8. 
68. Drulak, M.W., et al., Vaccination of seropositive subjects wi th CHIRON CMV gB subunit vaccine 
combined with MF59 adjuvant for production of CMV immune globulin.  Viral Immunology, 2000. 13(1): p. 
49-56. 
69. Ohizumi, Y., et al., Human cytomegalovirus neutralizing antibody response in Japanese children with bone 
marrow transplantation.  Tohoku Journal of Experimental Medicine, 1994. 174(1): p. 11-7. 
70. Hammond, D., CytoGam infusions at home.  Journal of Intravenous Nursing, 1999. 22(6): p. 331-5. 
71. Tzakis, A.G., Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver 
and intestinal transplantation.  Transplant Infectious Disease, 2001. [ADDRESS_896944] 2 : p. 35-9. 
72. Falagas, M.E., et al., Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased 
survival after orthotopic liver transplantation. The [LOCATION_011] Center for Liver Transplantation CMVIG Study 
Group.  Clinical Transplantation, 1997. 11(5 Pt 1): p. 432-7. 
73. Kleihauer, A., et al., Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by [CONTACT_79336]-
pulsed dendritic cells.  British Journal of Haematology, 2001. 113(1): p. 231-9. 
74. Cho, H.I., et al., Generation of Cytotoxic T Lymphocytes Specific for Human Cytomegalovirus Using 
Dendritic Cells In Vitro.  Journal of Immunotherapy, 2001. 24(3): p. 242-249. 
75. Raftery, M.J., et al., Dendritic cells cross-presenting viral antigens derived from autologous cells as a 
sensitive tool for visualization of human cytomegalovirus-reactive CD8+ T cells.  Transplantation, 2002. 
73(6): p. 998-1002. 
76. Peggs, K., et al., Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire 
diversity following in vitro restimulation by [CONTACT_488]-pulsed dendritic cells.  Blood, 2002. 99(1): p. 213-23. 
ELEVATE 
Version: 20181120 
 
66 
 77. Szmania, S., et al., Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical 
scale from a single blood draw usin g dendritic cells and HLA-tetramers.  Blood, 2001. 98(3): p. 505-12. 
78. Morse, M.A., et al., Immunotherapy with autologous, human dendritic cells transfected with 
carcinoembryonic antigen mRNA.  Cancer Investigation., 2003. 21(3): p. 341-9. 
79. Van Meirvenne, S., et al., Efficient genetic modification of murine dendritic cells by [CONTACT_664124].  Cancer Gene Ther, 2002. 9(9): p. 787-97. 
80. Van Tendeloo, V.F., et al., Highly efficient gene delivery by [CONTACT_664125]: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for 
tumor antigen loading of dendritic cells.  Blood, 2001. 98(1): p. 49-56. 
81. Ponsaerts, P., et al., Messenger RNA electroporation of human monocytes, followed by [CONTACT_664126], leads to highly stimulatory antigen-loaded mature dendritic cells.  J Immunol, 2002. 169(4): 
p. 1669-75. 
82. Ponsaerts, P., et al., mRNA-electroporated mature dendritic cells retain transgene expression, phenotypi[INVESTIGATOR_570017].  Leukemia, 2002. 16(7): p. 1324-30. 
83. Boczkowski, D., et al., Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in 
vivo.  Journal of Experimental Medicine, 1996. 184(2): p. 465-472. 
84. Strobel, I., et al., Human dendritic cells transfected with eith er RNA or DNA encoding influenza matrix 
protein M1 differ in their ability to stimulate cytotoxic T lymphocytes.  Gene Therapy, 2000. 7(23): p. 2028-
35. 
85. Kim, J.J., et al., Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.  
Oncogene, 1998. 17(24): p. 3125-35. 
86. Sercarz, E.E., et al., Dominance and crypticity of T cell antigenic determinants.  Annual Review of 
Immunology, 1993. 11: p. 729-66. 
87. Kundig, T.M., et al., On the role of antigen in maintaining cytotoxic T-cell memory.  Proceedings of the 
National Academy of Sciences of the [LOCATION_002] of America, 1996. 93(18): p. 9716-23. 
88. Kobayashi, T., et al., Tumor mRNA-loaded dendritic cells elicit tumo r-specific CD8(+) cytotoxic T cells in 
patients with malignant glioma.  Cancer Immunology Immunotherapy, 2003. 52: p. 632-7. 
89. Stupp, R., et al., Promising survival for patients with newly diagnosed glioblastoma multiforme treated 
with concomitant radiation plus temozolomide followed by [CONTACT_217418].  Journal of Clinical 
Oncology., 2002. 20(5): p. 1375-82. 
90. Hegi, M.E., et al., MGMT gene silencing and benefit from temozolomide in glioblastoma.  New England 
Journal of Medicine, 2005. 352: p. 997-1003, 2005 Mar 10. 
91. Su, Y.B., et al., Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity 
with therapeutic implications.  Journal of Clinical Oncology, 2004. 22(4): p. 610-6. 
92. Abramowicz, D., Daclizumab to prevent acute rej ection in renal transplantation.  N Engl J Med, 1998. 
338(23): p. 1700-1. 
93. Walker, R.E., et al., Long-term in vivo survival of receptor-modified syngeneic T cells in patients with 
human immunodeficiency virus infection.  Blood, 2000. 96(2): p. 467-74. 
94. Dillman, R.O., et al., Tumor localization by [CONTACT_664127]-111 in 
patients with metastatic renal cell carcin oma, melanoma, and colorectal cancer.  Cancer Biother 
Radiopharm, 1997. 12(2): p. 65-71. 
95. Sadelain, M., R. Brentjens, and I. Riviere, The promise and potential pi[INVESTIGATOR_664089].  
Curr Opin Immunol, 2009. 21(2): p. 215-23. 
96. Food and Drug Administration, H.a.H.S., Biological products; bacterial vaccines and toxoids; 
implementation of efficacy review. Final rule and final order.  2004: Federal Register. p. 255-267. 
97. Atkinson, W.L., et al., General recommendations on immunizatio n. Recommendations of the Advisory 
Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP) . 
2002: Centers for Disease Cont rol and Prevention. p. 1-35. 
98. Myers, M.G., et al., Primary immunization with tetanus and diphtheria toxoids. Reaction rates and 
immunogenicity in older children and adults.  JAMA, 1982. 248(19): p. 2478-2480. 
99. Vitek, C.R. and M. Wharton, Diphtheria Toxoid . [ADDRESS_896945] otkin, W.A. Orenstein, and 
P.A. Offit. 2008: Saunders. 
100. Baxter, D., Active and passive immunity, vaccin e types, excipi[INVESTIGATOR_34514].  Occupational Medicine, 
2007. 57(8): p. 552-556. 
101. Heimberger, A.B., et al., Bone marrow-derived dendritic cells pulsed with tumor homogenate induce 
immunity against syngeneic intracerebral glioma.  Journal of Neuroimmunology, 2000. 103(1): p. 16-25. 
ELEVATE 
Version: [ADDRESS_896946] central nervous system tumors.  Journal of Experimental Medicine, 
1997. 186(7): p. 1177-1182. 
103. Liau, L., et al., Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with 
tumor antigens.  Journal of Neurosurgery, 1999. 90(6): p. 1115-1124. 
104. Heimberger, A.B., et al., Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity 
and are effective against murine intracerebral melanoma.  Neurosurgery, 2002. 50: p. 158-166. 
105. Bodmer, S., et al., Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential 
production of transforming growth factor-beta 2.  Journal of Immunology, 1989. 143(10): p. 3222-3229. 
106. Kuppner, M.C., et al., The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 
inhibits the generation of lymphokine- activated killer (LAK) cells.  International Journal Cancer, 1988. 
42(4): p. 562-567. 
107. Maxwell, M., et al., Effect of the expression of transforming growth factor-beta 2 in primary human 
glioblastomas on immunosuppression and loss of immune surveillance.  J.Neurosurg., 1992. 76(5): p. 799-
804. 
108. Wahl, S.M., et al., Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-
1-dependent lymphocyte proliferation.  Journal of Immunology, 1988. 140(9): p. 3026-3032. 
109. Zuber, P., M.C. Kuppner, and N. de Tribolet, Transforming growth factor-beta [ADDRESS_896947] 
antigen expression on human malignant glioma cells.  European Journal of Immunology, 1988. 18(10): p. 
1623-1626. 
110. McHugh, R.S. and E.M. Shevach, Cutting edge: depletion of CD4+CD25+  regulatory T cells is necessary, 
but not sufficient, for induction of organ-specific autoimmune disease.  Journal of Immunology., 2002. 
168(12): p. 5979-83. 
111. Kohm, A.P., et al., Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive 
immune responses and central nervous system inflammation during active experimental autoimmune 
encephalomyelitis.  Journal of Immunology, 2002. 169(9): p. 4712-6. 
112. Shimizu, J., S. Yamazaki, and S. Sakaguchi, Induction of tumor immunity by [CONTACT_664128]25+CD4+ T 
cells: a common basis between tumor immunity and autoimmunity.  Journal of Immunology., 1999. 163(10): 
p. 5211-8. 
113. Steitz, J., et al., Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-
transduced dendritic cells enhance the interferon al pha-induced, CD8(+) T-cell-dependent immune defense 
of B16 melanoma.  Cancer Research., 2001. 61(24): p. 8643-6. 
114. Sutmuller, R.P., et al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of 
CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of 
autoreactive cytotoxic T lymphocyte responses.  Journal of Experimental Medicine., 2001. 194(6): p. 823-
32. 
115. Fecci, P.E., et al., Systemic CTLA-4 blockade ameliorates g lioma-induced changes to the CD4+ T-cell 
compartment without affecting regulatory T-cell function.  Journal of Experimental Medicine, 2006. 
Submitted . 
116. Fecci, P.E., et al., Systemic Anti-CD25 Monoclonal Antibody Administration Safely Enhances Immunity in 
Murine Glioma without Eliminating Regulatory T Cells.  Clin Cancer Res, 2006. 12(14): p. 4294-4305. 
117. Romani, N., et al., Generation of mature dendritic cells from human blood. An improved method with 
special regard to clinical applicability.  Journal of Immunological Methods, 1996. 196: p. 137-151. 
118. Yu, J.S., et al., Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic 
cytotoxicity and intracranial T-cell infiltration.  Cancer Research, 2001. 61(3): p. 842-7. 
119. Kikuchi,  T., et al., Results of a phase I clinical trial of vaccination of glioma patients with fusions of 
dendritic and glioma cells.  Cancer Immunology & Immunotherapy., 2001. 50(7): p. 337-44. 
120. Yamanaka, R., et al., Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells 
elicits immune responses: results of a clinical phase I/II trial.  British Journal of Cancer, 2003. 89(7): p. 
1172-9. 
121. Liau, L.M., et al., Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-
cell responses modulated by [CONTACT_664129].  Clinical Cancer 
Research, 2005. 11: p. 5515-25. 
122. Kikuchi,  T., et al., Vaccination of glioma patients with fusions of dendritic and glioma cells and 
recombinant human interleukin 12.  Journal of Immunotherapy with Emphasis on Tumor Immunology, 
2004. 27: p. 452-9. 
ELEVATE 
Version: 20181120 
 
68 
 123. Boskovitz, A., et al., Monoclonal antibodies for brain tumour treatment.  Expert Opi[INVESTIGATOR_570012] 2004. 4(9): p. 1453-71, [ADDRESS_896948] established intracerebral tumors.  Clinical Cancer Research., 2003. 9: p. 4247-4254. 
125. Mitchell, D.A., Batich, K.*, Gunn, M.D., Huang, M.N., Sanchez-Perez, L., Nair, S.K., Congdon, K.L., 
Reap, E., Archer, G.E., Desjardins, A., Friedman, A.H., Friedman, H.S., Herndon II, J.E., Coan, A., 
McLendon, R.E., Reardon, D.A., Vredenburgh, J.J., Bigner, D.D., and Sampson, J.H. , Tetanus toxoid and 
CCL3 improve DC vaccines in mice and glioblastoma patients.  Accepted with minor revisions, Nature , 
2014. 
126. Martin-Fontech a, A., et al., Regulation of dendritic cell migration to the draining lymph node: impact on T 
lymphocyte traffic and priming.  Journal of Experimental Medicine, 2003. 198: p. 615-21, 2003 Aug 18. 
127. Wen, P.Y., et al., Updated response assessment criteria for high -grade gliomas: response assessment in 
neuro-oncology working group.  J Clin Oncol, 2010. 28(11): p. 1963-72. 
128. Ratain, M.J., Sargent, Daniel J., Optimising the design of Phase II oncology trials: The importance of 
randomisation.  European Journal of Cancer, 2009. 45: p. 275-280. 
129. Rubinstein L, C.J., Ivy P, LeBlanc M, Sargent D, Randomized phase II designs.  Clin Cancer Res, 2009. 
15(6): p. 1883-1890. 
130. Rubinstein LV, K.E., Friedlin B, Hunsberger S, Ivy SP, Smith MA., Design issues of randomized phase II 
trials and a proposal for phase II screening trials.  Journal of Clinical Oncology, 2005. 23(28): p. 7199-
7206. 
131. DA, S., The asymptotic properties of nonparametric tests for comparing survival distributions.  Biometrika 
1981. 63: p. 316-319. 
132. Lakatas, E., Designing complex group sequential survival trials.  Statistics in medicine, 2002. 21: p. 1969-
1989. 
133. Lakatos, E., Sample sizes based on the log-rank statistic in complex clinical trials.  Biometrics 1988. 44: p. 
229-291. 
134. J., H., PASS 2008.  NCSS, LLC: Kaysville, UT, 2008. 
  
ELEVATE 
Version: 20181120 
 
69 
 18  APPENDICES 
18.1 Research Summary 
See eIRB.  
ELEVATE 
Version: 20181120 
 
70 
 18.2 SOPs and FORMS 
Separate upload in the protocol section in eIRB. 
  
ELEVATE 
Version: [ADDRESS_896949] Radiation Therapy 
Radiotherapy typi[INVESTIGATOR_34521] ≤ 5 weeks of surgery. One treatment of 1.8-2.0 Gy/fraction 
will be given daily 5 days per week for a total of 59.4-60.0 Gy ove r <7 weeks. 3D conformal and 
intensity-modulated RT is permitted. All portals should be treated during each treatment session. 
Doses are specified as the target dose that shall be to the center of the target volume.   The gross target volume (GTV ) for both the initial volume (G TV1) and the conedown volume 
(GTV2) should be based on the postoperative CT/M RI (and preferably the MRI; the preoperative 
scans may be used if postoperativ e scans are not available). This  initial target volume (GTV1) 
should include the contrast-enhan cing lesion (and should include the surgical resection cavity) 
and surrounding edema (if it exists) demonstrated  on CT/MRI plus a 2.0-cm margin (this 2.0-cm 
margin-extended volume will be considered the in itial planning target volume, or PTV1). The 
initial target volume should be treated to 46 Gy at 2Gy/fracti on or 45-50.4 Gy at 1.8Gy/fraction. 
If no surrounding edema is presen t, the initial planning target volume (PTV1) should include the 
contrast-enhancing lesion (and should include the surgical resecti on cavity) plus a 2.5-cm 
margin. Please note that clinical judgment may be used to modify PTV1 to exclude sensitive 
structures such as the optic chiasm, non-cranial contents, or anatomic regions in the brain where 
natural barriers would likely preclude microscopi c tumor extension, such as the cerebellum, the 
contralateral hemisphere, directly across from th e tentorium cerebri, the ventricles, etc. After 46 
Gy, the tumor volume (GTV2) for the conedown treatment should include the contrast-enhancing lesion (without edema) on the pre-su rgery CT/MRI scan plus a 1.5-2-cm margin 
(PTV2). Treat to 14 Gy at 2Gy/fraction or 14.4- 9.0 Gy at 1.8Gy/fraction to a total of 60.[ADDRESS_896950] 95% of the ta rget volume receives he 
prescribed dose. The optic apparatus should be limited to a ma ximum of 54Gy and no more than 5% of the 
volume of the brainstem should receive >54Gy.  Radiation should be delayed or in terrupted if the platelet coun t is < 20,000. Radiation should not 
begin or resume until the platelet count is ≥ 20,000. Hematologic toxicities should be rated on a 
scale of 0-5 as defined in the NCI Common Te rminology Criteria for Adverse Events (CTCAE) 
version 3.0.  If radiotherapy has to be temporaril y interrupted for technical or medical reasons 
unrelated to the temozolomide administration, th en treatment with daily temozolomide should 
continue. If radiotherapy has to be perman ently interrupted then treatment with daily 
temozolomide should stop.  The following should be  recorded at entry into this study: daily 
treatment record, all isodose distributions (i n color), dose volume histograms including the 
cumulative dose to the target volumes, optic chiasm, optic nerves and brain stem, and the 
radiotherapy summary.   
ELEVATE 
Version: [ADDRESS_896951] oaded in the drug section in eIRB. 
  
ELEVATE 
Version: 20181120 
 
73 
 18.5 DCI Data and Safety  Monitoring Plan 
Separate upload in the protocol section in eIRB. 
  
ELEVATE 
Version: 20181120 
 
74 
  
18.6 Duke PRTBTC DSMBplus Charter 
Separate upload in the protocol section in eIRB. 
  
ELEVATE 
Version: 20181120 
 
75 
  
18.7 Basiliximab Package Insert 
Separate upload in the protocol section in eIRB. 